AdaptHealth (AHCO) 10-Q 6 Nov 20 2020 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2020	Nov. 04, 2020
Document Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Sep. 30, 2020
Entity File Number	001-38399
Entity Registrant Name	AdaptHealth Corp.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	82-3677704
Entity Address, Address Line One	220 West Germantown Pike
Entity Address, Address Line Two	Suite 250
Entity Address, City or Town	Plymouth Meeting
Entity Address, State or Province	PA
Entity Address, Postal Zip Code	19462
City Area Code	610
Local Phone Number	630-6357
Title of 12(b) Security	Class A Common Stock, par value $0.0001 per share
Trading Symbol	AHCO
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Central Index Key	0001725255
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q3
Amendment Flag	false
Class A Common Stock
Document Information [Line Items]
Entity Common Stock, Shares Outstanding		63,882,204
Class B Common Stock
Document Information [Line Items]
Entity Common Stock, Shares Outstanding		25,751,706

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 272,318	$ 76,878
Accounts receivable	147,335	78,619
Inventory	46,477	13,239
Prepaid and other current assets	18,255	12,679
Total current assets	484,385	181,415
Equipment and other fixed assets, net	101,656	63,559
Goodwill	810,480	266,791
Identifiable intangible assets, net	94,725
Other assets	6,466	6,851
Deferred tax assets	51,114	27,505
Total Assets	1,548,826	546,121
Current liabilities:
Accounts payable and accrued expenses	192,337	102,728
Current portion of capital lease obligations	19,699	19,750
Current portion of long-term debt	8,479	1,721
Contract liabilities	13,231	9,556
Other liabilities	81,059	17,139
Total current liabilities	314,805	150,894
Long-term debt, less current portion	722,730	395,112
Other long-term liabilities	71,576	29,364
Total Liabilities	1,109,111	575,370
Commitments and contingencies (note 14)
Stockholders' Equity (Deficit)
Preferred Stock, par value of $0.0001 per share, 5,000,000 shares authorized; 183,560 and 0 shares issued and outstanding as of September 30, 2020 and December 31, 2019, respectively	1
Additional paid-in capital	476,861	11,252
Accumulated deficit	(23,130)	(27,210)
Accumulated other comprehensive income	(5,111)	1,431
Total stockholders' equity (deficit) attributable to AdaptHealth Corp.	448,630	(14,520)
Noncontrolling interest in subsidiaries	(8,915)	(14,729)
Total Stockholders' Equity (Deficit)	439,715	(29,249)
Total Liabilities and Stockholders' Equity (Deficit)	1,548,826	546,121
Class A Common Stock
Stockholders' Equity (Deficit)
Common stock	6	4
Class B Common Stock
Stockholders' Equity (Deficit)
Common stock	$ 3	$ 3

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2020	Dec. 31, 2019
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	183,560	0
Preferred stock, shares outstanding (in shares)	183,560	0
Class A Common Stock
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	210,000,000	210,000,000
Common stock, shares issued (in shares)	62,680,967	40,816,292
Common stock, shares outstanding (in shares)	62,680,967	40,816,292
Class B Common Stock
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	35,000,000	35,000,000
Common stock, shares issued (in shares)	25,874,704	31,563,799
Common stock, shares outstanding (in shares)	25,874,704	31,563,799

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Revenue:
Net revenue	$ 284,405	$ 136,451	$ 707,960	$ 380,103
Revenue, Product and Service [Extensible List]	us-gaap:HealthCarePatientServiceMember	us-gaap:HealthCarePatientServiceMember	us-gaap:HealthCarePatientServiceMember	us-gaap:HealthCarePatientServiceMember
Costs and expenses:
Cost of net revenue	$ 240,720	$ 114,797	$ 604,777	$ 317,174
Cost, Product and Service [Extensible List]	us-gaap:HealthCarePatientServiceMember	us-gaap:HealthCarePatientServiceMember	us-gaap:HealthCarePatientServiceMember	us-gaap:HealthCarePatientServiceMember
General and administrative expenses	$ 26,306	$ 12,090	$ 57,745	$ 31,508
Depreciation and amortization, excluding patient equipment depreciation	4,120	840	6,398	2,439
Total costs and expenses	271,146	127,727	668,920	351,121
Operating income	13,259	8,724	39,040	28,982
Interest expense, net	12,406	10,756	27,826	31,651
Loss on extinguishment of debt	5,316		5,316	2,121
Income (loss) before income taxes	(4,463)	(2,032)	5,898	(4,790)
Income tax (benefit) expense	(636)	1,027	2,290	5,444
Net income (loss)	(3,827)	(3,059)	3,608	(10,234)
Income (loss) attributable to noncontrolling interest	(1,338)	627	2,222	1,336
Net income (loss) attributable to AdaptHealth Corp.	$ (2,489)	$ (3,686)	$ 1,386	$ (11,570)
Net income (loss) per common share:
Basic	$ (0.04)	$ (0.17)	$ 0.03	$ (0.60)
Diluted	$ (0.04)	$ (0.17)	$ 0.02	$ (0.60)
Weighted average shares outstanding for net income (loss) attributable to AdaptHealth Corp.:
Basic	57,372	21,721	47,986	19,130
Diluted	57,372	21,721	50,848	19,130

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income (Loss) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Consolidated Statements of Comprehensive Income (Loss)
Net income (loss)	$ (3,827)	$ (3,059)	$ 3,608	$ (10,234)
Other comprehensive loss:
Interest rate swap agreements, inclusive of reclassification adjustment	925	850	(11,558)	850
Comprehensive income (loss)	(2,902)	(2,209)	(7,950)	(9,384)
Net income attributable to noncontrolling interests	(1,338)	627	2,222	1,336
Comprehensive income (loss) attributable to AdaptHealth Corp.	$ (1,564)	$ (2,836)	$ (10,172)	$ (10,720)

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholders' Equity (Deficit) / Members' Equity (Deficit) - USD ($) shares in Thousands, $ in Thousands	Class A Common StockCommon StockPrivate Placement [Member]	Class A Common StockCommon StockPublic Offering [Member]	Class A Common StockCommon Stock	Class A Common Stock	Class B Common StockCommon Stock	Members interest	Preferred StockPrivate Placement [Member]	Preferred Stock	Additional paid-in capitalPrivate Placement [Member]	Additional paid-in capitalPublic Offering [Member]	Additional paid-in capital	Accumulated Deficit	Accumulated other comprehensive income	Noncontrolling interests in subsidiaries	Private Placement [Member]	Public Offering [Member]	Total
Members equity, Beginning Balance at Dec. 31, 2018						$ 113,274						$ (13,371)		$ 2,865			$ 102,768
Limited Liability Company (LLC) Members' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]
Issuance of members' interest, net of offering costs of $837						19,163											19,163
Redemption of members' interest						(2,112)						(1,601)					(3,713)
Distributions to members												(250,000)					(250,000)
Equity-based compensation						5,223											5,223
Members equity, Ending Balance at Mar. 31, 2019						135,548						(270,773)		3,213			(132,012)
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]
Net income (loss)												(5,801)		348			(5,453)
Members equity, Beginning Balance at Dec. 31, 2018						113,274						(13,371)		2,865			102,768
Members equity, Ending Balance at Sep. 30, 2019						136,131						(276,542)	$ 850	2,863			(136,698)
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]
Net income (loss)																	(10,234)
Members equity, Beginning Balance at Mar. 31, 2019						135,548						(270,773)		3,213			(132,012)
Limited Liability Company (LLC) Members' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]
Equity-based compensation						183											183
Distributions to noncontrolling interest														(1,338)			(1,338)
Members equity, Ending Balance at Jun. 30, 2019						135,731						(272,856)		2,236			(134,889)
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]
Distributions to noncontrolling interest														(1,338)			(1,338)
Net income (loss)												(2,083)		361			(1,722)
Equity-based compensation						400											400
Members equity, Ending Balance at Sep. 30, 2019						$ 136,131						(276,542)	850	2,863			(136,698)
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]
Net income (loss)												(3,686)		627			(3,059)
Change in fair value of interest rate swaps, inclusive of reclassification adjustment													850				850
Balance at beginning of period at Dec. 31, 2019			$ 4		$ 3						$ 11,252	(27,210)	1,431	(14,729)			(29,249)
Shares, Outstanding, Beginning Balance at Dec. 31, 2019			40,816		31,564
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]
Issuance of common stock for acquisitions											6,248						6,248
Issuance of common stock for acquisitions (in shares)			387
Exchange of Class B Common Stock for Class A Common Stock											(361)			361
Exchange of Class B Common Stock for Class A Common Stock (in shares)			1,000		(1,000)
Shares issued in cashless exercise of warrants (in shares)			1,092
Equity-based compensation											2,223						2,223
Equity-based compensation (in shares)			59
Net income (loss)												(158)		424			266
Equity activity resulting from Tax Receivable Agreement											2,482						2,482
Change in fair value of interest rate swaps, inclusive of reclassification adjustment													(6,570)	(4,847)			(11,417)
Balance at end of period at Mar. 31, 2020			$ 4		$ 3						21,844	(27,368)	(5,139)	(18,791)			(29,447)
Shares, Outstanding, Ending Balance at Mar. 31, 2020			43,354		30,564
Balance at beginning of period at Dec. 31, 2019			$ 4		$ 3						11,252	(27,210)	1,431	(14,729)			$ (29,249)
Shares, Outstanding, Beginning Balance at Dec. 31, 2019			40,816		31,564
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]
Sale of stock (in shares)																	2,100
Shares issued in cashless exercise of warrants (in shares)				2,000													900
Net income (loss)																	$ 3,608
Balance at end of period at Sep. 30, 2020			$ 6		$ 3			$ 1			476,861	(23,130)	(5,111)	(8,915)			439,715
Shares, Outstanding, Ending Balance at Sep. 30, 2020			62,681		25,875			184
Limited Liability Company (LLC) Members' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]
Distributions to noncontrolling interest														(800)			(800)
Balance at beginning of period at Mar. 31, 2020			$ 4		$ 3						21,844	(27,368)	(5,139)	(18,791)			(29,447)
Shares, Outstanding, Beginning Balance at Mar. 31, 2020			43,354		30,564
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]
Exchange of Class B Common Stock for Class A Common Stock											(1,580)			1,580
Exchange of Class B Common Stock for Class A Common Stock (in shares)			2,055		(2,055)
Exchange of Class A Common Stock for Series B-1 Preferred Stock			$ (2)					$ 1			1
Exchange of Class A Common Stock for Series B-1 Preferred Stock (in shares)			(15,810)					158
Distributions to noncontrolling interest														(800)			(800)
Cashless exercise of warrants			$ 1								11,882						11,883
Shares issued in cashless exercise of warrants (in shares)			1,034
Equity-based compensation											3,244						3,244
Equity-based compensation (in shares)			32
Net income (loss)												4,033		3,136			7,169
Equity activity resulting from Tax Receivable Agreement											2,223						2,223
Change in fair value of interest rate swaps, inclusive of reclassification adjustment													(656)	(410)			(1,066)
Balance at end of period at Jun. 30, 2020			$ 3		$ 3			$ 1			37,614	(23,335)	(5,795)	(15,285)			(6,794)
Shares, Outstanding, Ending Balance at Jun. 30, 2020			30,665		28,509			158
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]
Issuance of common stock for acquisitions			$ 1								83,280						83,281
Issuance of common stock for acquisitions (in shares)			4,344
Sale of stock, net of offering costs	$ 1	$ 1							$ 223,360	$ 133,041					$ 223,361	$ 133,042
Sale of stock (in shares)	10,930	9,200					75
Exchange of Class B Common Stock for Class A Common Stock											(7,467)			7,467
Exchange of Class B Common Stock for Class A Common Stock (in shares)			2,634		(2,634)
Cashless exercise of warrants											12,612						12,612
Shares issued in cashless exercise of warrants (in shares)			1,979
Equity-based compensation											5,502						5,502
Equity-based compensation (in shares)			35
Conversion of Series B-2 Preferred Stock to Series B-1 Preferred Stock (in shares)								(9)
Conversion of Series A Preferred Stock to Class A Common Stock (in shares)			2,888					(40)
Class A Common Stock issued in connection with Employee Stock Purchase Plan (in shares)			6
Net income (loss)												(2,489)		(1,338)			(3,827)
Equity activity resulting from Tax Receivable Agreement											2,236						2,236
Equity activity resulting from the impact of other changes in ownership and deferred taxes											(10,623)						(10,623)
Equity activity resulting from the Put/Call Agreement											(2,694)	2,694
Change in fair value of interest rate swaps, inclusive of reclassification adjustment													684	241			925
Balance at end of period at Sep. 30, 2020			$ 6		$ 3			$ 1			$ 476,861	$ (23,130)	$ (5,111)	$ (8,915)			$ 439,715
Shares, Outstanding, Ending Balance at Sep. 30, 2020			62,681		25,875			184

Consolidated Statements Of Ch_2

Consolidated Statements Of Changes in Stockholders' Equity (Deficit) (Parenthetical) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended		9 Months Ended
	Jul. 31, 2020	Sep. 30, 2020	Mar. 31, 2019	Sep. 30, 2020	Sep. 30, 2019
Offering costs			$ 837	$ 11,197	$ 837
Private Placement [Member]
Offering costs	$ 1,600	$ 1,639
Public Offering [Member]
Offering costs		$ 9,558

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Cash flows from operating activities:
Net income (loss)	$ 3,608	$ (10,234)
Adjustments to reconcile net (loss) income to net cash provided by operating activities:
Depreciation and amortization, including patient equipment depreciation	55,186	45,077
Equity-based compensation	10,969	5,806
Deferred income tax (benefit) expense	(564)	2,115
Change in fair value of interest rate swaps, net of reclassification adjustment	(2,130)	12,141
Change in fair value of contingent consideration	(2,900)
Payment of contingent consideration in connection with acquisition - operating	(1,000)
Amortization of intangible assets	2,675	0
Amortization of deferred financing costs	1,189	830
Amortization of bond discount	128
Imputed interest expense	46
Write-off of deferred financing costs	5,316	2,121
Gain on sale of investment	(591)
Changes in operating assets and liabilities, net of effects from acquisitions:
Accounts receivable	(19,251)	(17,250)
Inventory	(10,166)	(2,388)
Prepaid and other assets	(1,459)	(2,381)
Accounts payable and accrued expenses and other current liabilities	104,231	7,337
Net cash provided by operating activities	145,287	43,174
Cash flows from investing activities:
Payments for business acquisitions, net of cash acquired	(605,309)	(47,946)
Purchases of equipment and other fixed assets	(22,834)	(14,453)
Payments for investments in cost-method companies	(1,000)
Proceeds from sale of investment	2,046
Net cash used in investing activities	(627,097)	(62,399)
Cash flows from financing activities:
Proceeds from borrowings on long-term debt and lines of credit	536,275	345,500
Repayments on long-term debt and lines of credit	(545,584)	(156,062)
Proceeds from the sale of Class A Common Stock and Series A Preferred Stock	225,000
Proceed from issuance of Class A Common Stock	142,600
Proceeds from the issuance of senior unsecured notes, net of related discount	343,875
Proceeds from exercise of warrants	24,495
Payments on capital leases	(29,710)	(28,660)
Payments for equity issuance costs	(11,197)	(837)
Payments of deferred financing costs	(6,754)	(9,028)
Distributions to noncontrolling interest	(800)	(1,338)
Payment of contingent consideration in connection with acquisition- financing	(200)	(13,000)
Payment of deferred purchase price in connection with an acquisition	(750)
Proceeds from issuance of promissory note payable		100,000
Proceeds from issuance of members' interests		20,000
Distributions to members		(250,000)
Payments for redemption of members' interest		(3,713)
Net cash provided by financing activities	677,250	2,862
Net increase (decrease) in cash and cash equivalents	195,440	(16,363)
Cash and cash equivalents - beginning of the period	76,878	25,186
Cash and cash equivalents - end of the period	272,318	8,823
Supplemental disclosures:
Cash paid for interest	22,788	15,769
Cash paid for income taxes	3,062	492
Noncash investing and financing activities:
Equipment acquired under capital lease obligations	28,888	29,565
Unpaid equipment and other fixed asset purchases at end of year	8,452	8,483
Equity consideration issued in connection with acquisitions	89,529
Contingent purchase price in connection with acquisitions	6,464	6,425
Seller note issued in connection with an acquisition		2,000
Deferred purchase price in connection with acquisitions	$ 33	$ 1,500

General Information

General Information	9 Months Ended
	Sep. 30, 2020
General Information
General Information	(1) General Information AdaptHealth Corp. and subsidiaries (AdaptHealth or the Company), f/k/a DFB Healthcare Acquisitions Corp. (DFB), is a leading provider of home healthcare equipment, medical supplies to the home and related services in the United States. The Company focuses primarily on providing (i) sleep therapy equipment, supplies and related services (including CPAP and bi PAP services) to individuals suffering from obstructive sleep apnea (OSA), (ii) medical devices and supplies to patients for the treatment of diabetes (including continuous glucose monitors and insulin pumps), (iii) home medical equipment (HME) to patients discharged from acute care and other facilities, (iv) oxygen and related chronic therapy services in the home, and (v) other HME medical devices and supplies on behalf of chronically ill patients with wound care, urological, incontinence, ostomy and nutritional supply needs. The Company services beneficiaries of Medicare, Medicaid and commercial insurance payors. ​ On July 8, 2019, AdaptHealth Holdings LLC (AdaptHealth Holdings) entered into an Agreement and Plan of Merger (the Merger Agreement), as amended on October 15, 2019, with DFB, pursuant to which AdaptHealth Holdings combined with DFB (the Business Combination). The Business Combination closed on November 8, 2019. Refer to Note 3, Significant Transactions ​ Unless the context otherwise requires, “the Company”, “we,” “us,” and “our” refer, for periods prior to the closing of the Business Combination, to AdaptHealth Holdings and its subsidiaries and, for periods upon or after the closing of the Business Combination, to AdaptHealth Corp. and its subsidiaries, including AdaptHealth Holdings and its subsidiaries. ​ The consolidated interim financial statements are unaudited, but reflect all normal recurring adjustments that are, in the opinion of management, necessary to fairly present the information set forth herein. The interim consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019. Interim results are not necessarily indicative of the results for a full year. ​ There have been no material changes in the Company’s significant accounting policies as compared to the significant accounting policies described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019. ​ (a) Basis of Presentation The consolidated interim financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP). In the opinion of management, the consolidated interim financial statements include all necessary adjustments for a fair presentation of the financial position and results of operations for the periods presented. The Business Combination was accounted for as a reverse recapitalization, with DFB treated as the acquired company and AdaptHealth Holdings as the acquirer, for financial reporting purposes. Therefore, the equity structure has been restated to that of the Company. The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act of 1933, as amended, (the Securities Act), as modified by the Jumpstart our Business Startups Act of 2012, (the JOBS Act), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and other exemptions. (b) Basis of Consolidation The accompanying consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. (c) Concentration of Credit Risk Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash and trade accounts receivable. The Company maintains its cash in bank deposit accounts, which, at times, may exceed federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk on cash and cash equivalents. (d) Accounting Estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and reported amounts of revenues and expenses during the reporting period. Management bases these estimates and assumptions upon historical experience, existing and known circumstances, authoritative accounting pronouncements and other factors that management believes to be reasonable. Significant areas requiring the use of management estimates relate to revenue recognition and the valuation of accounts receivable (implicit price concession), income taxes, contingent consideration, equity-based compensation, interest rate swaps, and long-lived assets, including goodwill. Actual results could differ from those estimates. (e) Valuation of Goodwill and Intangible Assets The Company has a significant amount of goodwill on its balance sheet that resulted from the business acquisitions the Company has made in recent years. Goodwill is not amortized and is tested for impairment annually and upon the occurrence of a triggering event or change in circumstances indicating a possible impairment. Such changes in circumstance can include, among others, changes in the legal environment, reimbursement environment, operating performance, and/or future prospects. The Company performs its annual impairment review of goodwill during the fourth quarter of each year. The impairment testing can be performed on either a quantitative or qualitative basis. The Company first assesses qualitative factors to determine whether it is necessary to perform quantitative goodwill impairment testing. If determined necessary, the Company applies the quantitative impairment test to identify and measure the amount of impairment, if any. Definite-lived intangible assets consist of payor contracts, developed technology and tradenames. These assets are amortized using the straight-line method over their estimated useful lives, which reflects the pattern in which the economic benefits of the assets are expected to be consumed. These assets are tested for impairment consistent with the Company’s long-lived assets. The following table summarizes the useful lives of the intangible assets acquired: ​ ​ ​ ​ ​ Payor contracts 10 ​ years Developed technology 5 ​ years Tradenames 5 10 ​ years ​ (f) Business Segment The Company’s chief operating decision-makers are its Chief Executive Officer and President, who make resource allocation decisions and assess performance based on financial information presented on an aggregate basis. There are no segment managers who are held accountable by the chief operating decision-makers, or anyone else, for any planning, strategy and key decision-making regarding operations. The corporate office is responsible for contract negotiation with vendors and payors, corporate compliance with healthcare laws and regulations, and revenue cycle management. Accordingly, the Company has a single reportable segment and operating segment structure. (g) Recently Issued Accounting Pronouncements In February 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2016-02, Leases (Topic 842) (ASU 2016-02), which amended authoritative guidance on accounting for leases. The new provisions require that a lessee of operating leases recognize a liability to make lease payments and a right-of-use asset representing its right to use the underlying asset for the lease term. The Company is required to adopt the new standard for the annual reporting period beginning January 1, 2022, and interim reporting periods beginning January 1, 2023. The adoption of this standard is expected to have a material impact on the Company’s financial position. The Company is still evaluating the impact on its results of operations and does not expect the adoption of this standard to have an impact on liquidity. In January 2017, the FASB issued ASU 2017-04, Intangibles - Goodwill and Other (ASC Topic 350): Simplifying the Test for Goodwill Impairment ​ In December 2019, the FASB issued ASU 2019-12, “ Simplifying the Accounting for Income Taxes ​ In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments ​ In March 2020, the FASB issued ASU No. 2020-04, Reference Rate Reform (Topic 848) ..

Revenue Recognition and Account

Revenue Recognition and Accounts Receivable	9 Months Ended
	Sep. 30, 2020
Revenue from Contract with Customer [Abstract]
Revenue Recognition and Accounts Receivable	(2) Revenue Recognition and Accounts Receivable Revenue Recognition The Company generates revenues for services and related products that the Company provides to patients for home medical equipment, related supplies, and other items. The Company’s revenues are recognized in the period in which services and related products are provided to customers and are recorded either at a point in time for the sale of supplies and disposables, or over the fixed monthly service period for equipment. Revenues are recognized when control of the promised good or service is transferred to customers, in an amount that reflects the consideration to which the Company expects to receive from patients or under reimbursement arrangements with Medicare, Medicaid and third-party payors, in exchange for those goods and services. Sales revenue is recognized upon transfer of control of products or services to customers in an amount that reflects the consideration the Company expects to receive in exchange for those products or services. Revenues for the sale of durable medical equipment and related supplies, including oxygen equipment, ventilators, wheelchairs, hospital beds and infusion pumps, are recognized at the time of delivery. ​ The Company provides certain equipment to patients which is reimbursed periodically in fixed monthly payments for as long as the patient is using the equipment and medical necessity continues (in certain cases, the fixed monthly payments are capped at a certain amount). The equipment provided to the patient is based upon medical necessity as documented by prescriptions and other documentation received from the patient’s physician. The patient generally does not negotiate or have input with respect to the manufacturer or model of the equipment prescribed by their physician and delivered by the Company. Once initial delivery of this equipment is made to the patient for initial setup, a monthly billing process is established based on the initial setup service date. The Company recognizes the fixed monthly revenue ratably over the service period as earned, less estimated adjustments, and defers revenue for the portion of the monthly bill that is unearned. No separate revenue is earned from the initial setup process. Included in fixed monthly revenue are unbilled amounts for which the revenue recognition criteria had been met as of period-end but were not yet billed to the payor. The estimate of net unbilled fixed monthly revenue recognized is based on historical trends and estimates of future collectability. ​ The Company disaggregates net revenue from contracts with customers by payor type and by core service lines. The Company believes that disaggregation of net revenue into these categories depicts how the nature, amount, timing and uncertainty of revenue and cash flows are affected by economic factors. The payment terms and conditions within the Company’s revenue-generating contracts vary by payor type and payor source. The composition of net revenue by payor type for the three and nine months ended September 30, 2020 and 2019 are as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended September 30, ​ Nine Months Ended September 30, ​ ​ 2020 ​ 2019 2020 ​ 2019 Insurance ​ $ 175,418 ​ $ 77,136 ​ $ 438,034 ​ $ 213,762 Government ​ ​ 81,967 ​ ​ 43,679 ​ ​ 193,725 ​ ​ 122,358 Patient pay ​ 27,020 ​ 15,636 ​ 76,201 ​ 43,983 Net revenue ​ $ 284,405 ​ $ 136,451 ​ $ 707,960 ​ $ 380,103 ​ The composition of net revenue by core service lines for the three and nine months ended September 30, 2020 and 2019 are as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended September 30, ​ Nine Months Ended September 30, ​ ​ 2020 ​ 2019 2020 ​ 2019 Net sales revenue: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Sleep ​ $ 74,655 ​ $ 59,117 ​ $ 227,970 ​ $ 156,677 Diabetes ​ ​ 52,887 ​ ​ — ​ ​ 64,566 ​ ​ — Supplies to the home ​ ​ 44,579 ​ ​ 1,966 ​ ​ 100,479 ​ ​ 5,910 Respiratory ​ 5,152 ​ 1,397 ​ 26,034 ​ 4,121 HME ​ ​ 14,998 ​ ​ 10,873 ​ ​ 39,304 ​ ​ 31,598 Other ​ ​ 14,869 ​ ​ 9,711 ​ ​ 38,725 ​ ​ 26,710 Total net sales revenue ​ $ 207,140 ​ $ 83,064 ​ $ 497,078 ​ $ 225,016 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net revenue from fixed monthly equipment reimbursements: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Sleep ​ $ 24,971 ​ $ 20,761 ​ $ 70,284 ​ $ 57,762 Diabetes ​ ​ 946 ​ ​ — ​ ​ 946 ​ ​ — Respiratory ​ 32,269 ​ 19,646 ​ 88,132 ​ 60,084 HME ​ ​ 14,256 ​ ​ 11,088 ​ ​ 39,695 ​ ​ 31,533 Other ​ ​ 4,823 ​ ​ 1,892 ​ ​ 11,825 ​ ​ 5,708 Total net revenue from fixed monthly equipment reimbursements ​ $ 77,265 ​ $ 53,387 ​ $ 210,882 ​ $ 155,087 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total net revenue: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Sleep ​ $ 99,626 ​ $ 79,878 ​ $ 298,254 ​ $ 214,439 Diabetes ​ ​ 53,833 ​ ​ — ​ ​ 65,512 ​ ​ — Supplies to the home ​ ​ 44,579 ​ ​ 1,966 ​ ​ 100,479 ​ ​ 5,910 Respiratory ​ 37,421 ​ 21,043 ​ 114,166 ​ 64,205 HME ​ ​ 29,254 ​ ​ 21,961 ​ ​ 78,999 ​ ​ 63,131 Other ​ ​ 19,692 ​ ​ 11,603 ​ ​ 50,550 ​ ​ 32,418 Total net revenue ​ $ 284,405 ​ $ 136,451 ​ $ 707,960 ​ $ 380,103 ​ In response to the COVID-19 pandemic and the National Emergency Declaration, dated March 13, 2020, the Company increased its cash liquidity by, among other things, seeking recoupable advance payments of $45.8 million made available by the Centers for Medicare & Medicaid Services (CMS) under the Coronavirus Aid, Relief, and Economic Security Act (the CARES Act) legislation, which was received in April 2020. The recoupment of such amount by CMS is expected to begin during 2021 and will be applied to services provided and revenue recognized during the period in which the recoupment occurs. In addition, in April 2020, the Company received distributions from the CARES Act provider relief funds of $17.2 million targeted to offset lost revenue and expenditures incurred in connection with the COVID-19 pandemic. The provider relief funds are subject to certain restrictions and are subject to recoupment if not used for designated purposes. The Company is currently in the process of determining how much of the CARES Act provider relief funds it will be entitled to based on the terms and conditions of the program, including recent guidance issued by the U.S. Department of Health and Human Services in October 2020. The total of the recoupable advance payments and the CARES Act provider relief funds of $63.0 million is included in other current liabilities in the consolidated balance sheets as of September 30, 2020. Accounts Receivable Due to the continuing changes in the healthcare industry and third-party reimbursement environment, certain estimates are required to record accounts receivable at their net realizable values. Inherent in these estimates is the risk that they will have to be revised or updated as additional information becomes available. The complexity of third-party billing arrangements and laws and regulations governing Medicare and Medicaid may result in adjustments to amounts originally recorded. The Company performs a periodic analysis to review the valuation of accounts receivable and collectability of outstanding balances. Management’s evaluation takes into consideration such factors as historical bad debt experience, business and economic conditions, trends in healthcare coverage, other collection indicators and information about specific receivables. The Company’s evaluation also considers the age and composition of the outstanding amounts in determining their estimated net realizable value. Included in accounts receivable are earned but unbilled accounts receivables. Billing delays, ranging from several days to several weeks, can occur due to the Company’s policy of compiling required payor specific documentation prior to billing for its services rendered. The Company recorded unbilled revenue of $18.5 million and $8.6 million as of September 30, 2020 and December 31, 2019, respectively.

Significant Transactions

Significant Transactions	9 Months Ended
	Sep. 30, 2020
Significant Transactions [Abstract]
Significant Transactions	(3) Significant Transactions Acquisitions During the nine months ended September 30, 2020 and 2019, the Company completed several acquisitions to strengthen its current market share in existing markets or to expand into new markets. The goodwill generated from these acquisitions is attributable to expected growth and cost synergies and the expected contribution of each acquisition to the Company’s overall strategy. The majority of the goodwill recorded during the nine months ended September 30, 2020 is expected to be deductible for tax purposes. The estimated fair values of the net assets of acquired businesses as described below are subject to change resulting from such items as working capital adjustments post-acquisition. As a result, the acquisition accounting for certain acquired businesses could change in subsequent periods resulting in adjustments to goodwill once finalized. Nine Months Ended September 30, 2020 On January 2, 2020, the Company purchased 100% of the equity interests of the Patient Care Solutions business (PCS), a subsidiary of McKesson Corporation. PCS is a home medical equipment supplies business. The Company allocated the consideration paid to the estimated fair values of the net assets acquired on a provisional basis, including $17.4 million to accounts receivable, $0.5 million to equipment and other fixed assets, $0.1 million to goodwill, and $4.0 million of net liabilities to other working capital accounts. On March 2, 2020, the Company purchased certain assets of the durable medical equipment business of Advanced Home Care, Inc. (Advanced). The Company allocated the consideration paid to the estimated fair values of the net assets acquired on a provisional basis, including $21.0 million to equipment and other fixed assets, $2.7 million to inventory, $0.6 million to identifiable intangible assets, $35.8 million to goodwill, and $1.6 million of net liabilities to other working capital accounts. The acquisition of Advanced also includes a potential contingent payment of up to $9.0 million based on certain conditions after closing. The Company is in the process of determining the fair value of such contingent payment, and as such an estimated fair value was not included in the consideration paid as part of the Company’s preliminary acquisition accounting. The valuation of such contingent consideration is expected to be completed during the fourth quarter of 2020. On July 1, 2020, the Company acquired 100% of the equity interests of Solara Medical Supplies, LLC (Solara). Solara is an independent distributor of continuous glucose monitors (“CGM”) in the United States and offers a comprehensive suite of direct-to-patient diabetes management supplies to patients throughout the country, including CGMs, insulin pumps and other diabetic supplies. The Company allocated the consideration paid to the estimated fair values of the net assets acquired on a provisional basis, including $12.1 million to cash, $15.1 million to accounts receivable, $15.0 million to inventory, $4.4 million to equipment and other fixed assets, $85.7 million to identifiable intangible assets, $347.1 million to goodwill, $22.4 million to accounts payable and accrued expenses, and $3.0 million of net liabilities to other working capital accounts. On July 1, 2020, the Company acquired 100% of the equity interests of ActivStyle, Inc. (ActivStyle). ActivStyle is a leading direct-to-consumer supply company that provides incontinence and urology products to patients throughout the United States. The Company allocated the consideration paid to the estimated fair values of the net assets acquired on a provisional basis, including $5.0 million to cash, $4.1 million to accounts receivable, $0.5 million to inventory, $1.0 million to equipment and other fixed assets, $10.1 million to identifiable intangible assets, $51.2 million to goodwill, $7.3 million to accounts payable and accrued expenses, and $0.9 million of assets to other working capital accounts. In addition, during the period, the Company completed acquisitions of certain individually immaterial businesses, the results of which were immaterial to the Company’s results for the three and nine months ended September 30, 2020. The following table summarizes the consideration paid for all acquisitions during the nine months ended September 30, 2020 (in thousands): ​ ​ ​ ​ ​ Cash consideration ​ $ 623,107 Equity consideration ​ 89,529 Contingent consideration ​ ​ 6,464 Deferred payments ​ 33 Total ​ $ 719,133 ​ The Company allocated the consideration paid to the net assets acquired based on their estimated acquisition date fair values. The Company is still evaluating the fair value of certain assets and liabilities for which provisional amounts were recorded and expects to finalize such evaluation either during the remainder of 2020 or during the first half of 2021. Based upon management’s evaluation, which is preliminary and subject to completion of working capital and other adjustments, the consideration paid was allocated as follows during the nine months ended September 30, 2020 (in thousands): ​ ​ ​ ​ ​ Cash ​ $ 17,798 Accounts receivable ​ 49,464 Inventory ​ 23,073 Prepaid and other current assets ​ 4,254 Equipment and other fixed assets ​ 42,852 Goodwill ​ 543,689 Intangible assets ​ ​ 97,400 Accounts payable and accrued expenses ​ (47,759) Contract liabilities ​ ​ (3,675) Other current liabilities ​ ​ (5,069) Other long-term liabilities ​ ​ (1,186) Capital lease obligations ​ (1,708) Net assets acquired ​ $ 719,133 ​ Nine Months Ended September 30, 2019 ​ On January 2, 2019, the Company purchased 100% of the equity of Gould’s Discount Medical, LLC (Goulds). Goulds is a home medical equipment and supplies business. The Company allocated the consideration paid to the estimated fair values of the net assets acquired on a provisional basis, including $3.7 million to accounts receivable, $2.4 million to inventory, $1.7 million to equipment and other fixed assets, $19.1 million to goodwill, and $2.6 million of net liabilities to other working capital accounts. The total consideration paid included potential contingent consideration payments in an aggregate amount of up to $1.5 million based on certain conditions after closing, which was determined to be the estimated fair value of such liability at the acquisition date. ​ On July 5, 2019, the Company purchased certain assets relating to the durable medical equipment business of SleepMed Therapies, Inc. (SleepMed). SleepMed provides positive airway pressure devices and related supplies to customers in their homes or other alternative site care facilities. The Company allocated the consideration paid to the estimated fair values of the net assets acquired on a provisional basis, including $0.3 million to inventory, $1.3 million to equipment and other fixed assets, $14.1 million to goodwill, and $0.3 million of net liabilities to other working capital accounts. The total consideration paid included potential contingent consideration payments in an aggregate amount of up to $4.0 million based on certain conditions after closing, which was determined to be the estimated fair value of such liability at the acquisition date. ​ In addition, during the period, the Company completed acquisitions of certain individually immaterial businesses, the results of which were immaterial to the Company’s results for the three and nine months ended September 30, 2019. ​ The following table summarizes the consideration paid for all acquisitions during the nine months ended September 30, 2019 (in thousands): ​ ​ ​ ​ Cash consideration $ 47,763 Seller note 2,000 Contingent consideration 6,425 Deferred payments ​ 1,500 Total $ 57,688 ​ The Company allocated the consideration paid to the net assets acquired based on their estimated acquisition date fair values. Based upon management’s evaluation, which was preliminary and subject to completion of working capital and other adjustments, the consideration paid was allocated as follows during the nine months ended September 30, 2019 (in thousands): ​ ​ ​ ​ ​ ​ Total Cash $ 117 Accounts receivable 3,404 Inventory 4,173 Prepaid and other current assets 12 Equipment and other fixed assets 10,238 Goodwill 43,883 Contract liabilities ​ (1,512) Accounts payable and accrued expenses (2,627) Net assets acquired $ 57,688 ​ The Company finalized the valuation of the fair value of the net assets acquired for these acquisitions during the remainder of 2019. During the nine months ended September 30, 2019, the Company paid net cash of $0.3 million relating to working capital adjustments associated with businesses that were acquired during 2018 which was recorded as an increase to goodwill during the period. Pro-Forma Information The unaudited pro-forma financial information presented below has been prepared by adjusting the historical results of the Company to include the historical results of the significant acquisitions described above. The unaudited pro-forma financial information is presented for illustrative purposes only and may not be indicative of the results of operations that would have actually occurred. In addition, future results may vary significantly from the results reflected in the pro-forma information. The unaudited pro-forma financial information does not reflect the impact of future events that may occur after the acquisitions, such as the impact of cost savings or other synergies that may result from these acquisitions, and does not include interest expense associated with debt incurred to fund the acquisitions. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ (in thousands) ​ Three Months Ended September 30, ​ Nine Months Ended September 30, ​ ​ ​ 2020 2019 2020 2019 ​ Net revenue ​ $ 284,405 ​ $ 255,731 ​ $ 835,177 ​ $ 732,999 ​ Operating income ​ $ 13,259 ​ $ 12,785 ​ $ 53,600 ​ $ 33,921 ​ ​ The pro-forma results for the three months ended September 30, 2020 are the same as the actual results in that period due to the acquisition dates of the significant acquisitions described above that occurred in that period. Results of Businesses Acquired The following table presents the amount of net revenue and operating income (loss) since the respective acquisition dates for the significant acquisitions described above that is included in the Company’s consolidated statements of operations for the three and nine months ended September 30, 2020 and 2019: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ (in thousands) ​ Three Months Ended September 30, ​ Nine Months Ended September 30, ​ ​ ​ 2020 2019 2020 2019 ​ Net revenue ​ $ 115,077 ​ $ 16,137 ​ $ 208,803 ​ $ 33,732 ​ Operating income (loss) ​ $ 4,637 ​ $ 1,872 ​ $ (2,984) ​ $ 5,285 ​ ​ The operating loss for the nine months ended September 30, 2020 is primarily due to operating losses related to PCS. ​ Business Combination ​ As discussed in Note 1, General Information ​ Following the Closing of the Business Combination, the holders of Class A Common Stock owned an approximate 56% direct controlling interest, with the remaining 44% direct noncontrolling interest owned by the former owners of AdaptHealth Holdings in the form of common units representing limited liability company interests in AdaptHealth Holdings from and after the Closing (New AdaptHealth Units), which is presented as noncontrolling interest in the consolidated financial statements. These members hold common unit interests of AdaptHealth Holdings and a corresponding number of shares of non-economic Class B Common Stock, which enables the holder to one vote per share. The New AdaptHealth Units and a corresponding number of shares of Class B Common Stock are exchangeable on a one-to-one basis for shares of Class A Common Stock. The holders of New AdaptHealth Units owned an approximate 24% direct noncontrolling economic interest in AdaptHealth Holdings at September 30, 2020. This direct noncontrolling interest will continue to decrease as New AdaptHealth Units and a corresponding number of shares of Class B Common Stock are exchanged for shares of Class A Common Stock. ​ Other investments During the nine months ended September 30, 2020, the Company paid an aggregate $1.0 million to acquire equity ownership and debt interests in certain companies. These investments are accounted for under the cost method of accounting.

Equipment and Other Fixed Asset

Equipment and Other Fixed Assets	9 Months Ended
	Sep. 30, 2020
Equipment and Other Fixed Assets
Equipment and Other Fixed Assets	(4) Equipment and Other Fixed Assets Equipment and other fixed assets as of September 30, 2020 and December 31, 2019 are as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, ​ December 31, ​ ​ 2020 2019 Patient medical equipment ​ $ 151,634 $ 112,071 Delivery vehicles ​ 7,150 4,461 Other ​ 25,023 15,474 ​ ​ 183,807 ​ 132,006 Less accumulated depreciation ​ (82,151) ​ (68,447) ​ ​ $ 101,656 ​ $ 63,559 ​

Goodwill and Identifiable Intan

Goodwill and Identifiable Intangible Assets	9 Months Ended
	Sep. 30, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Identifiable Intangible Assets	(5) Goodwill and Identifiable Intangible Assets Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. The change in the carrying amount of goodwill for the nine months ended September 30, 2020 was as follows (in thousands): ​ ​ ​ ​ ​ Balance at December 31, 2019 ​ $ 266,791 Acquired goodwill during the period ​ ​ 543,689 Balance at September 30, 2020 ​ $ 810,480 ​ The Company did not record any goodwill impairment charges during the three and nine months ended September 30, 2020 and 2019. ​ Identifiable intangible assets that are separable and have determinable useful lives are valued separately and amortized over the period which reflects the pattern in which the economic benefits of the assets are expected to be consumed. There were no identifiable intangible assets at December 31, 2019. Identifiable intangible assets consisted of the following at September 30, 2020 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted-Average ​ ​ ​ ​ ​ Remaining Life (Years) Payor contracts, net of accumulated amortization of $1,500 ​ $ 58,500 ​ 9.8 Developed technology, net of accumulated amortization of $345 ​ ​ 6,655 ​ 4.8 Tradenames, net of accumulated amortization of $830 ​ ​ 29,570 ​ 9.5 Identifiable intangible assets, net ​ $ 94,725 ​ ​ ​ Amortization expense related to identifiable intangible assets, which is included in depreciation and amortization, excluding patient equipment depreciation, in the accompanying statements of operations, was $2.7 million for both the three and nine months ended September 30, 2020. There was no amortization expense related to identifiable intangible assets for the three and nine months ended September 30, 2019. ​ Future amortization expense related to identifiable intangible assets is estimated to be as follows (in thousands): ​ ​ ​ ​ ​ Twelve months ending September 30, ​ ​ 2021 ​ $ 10,650 2022 ​ 10,596 2023 ​ 10,596 2024 ​ 10,596 2025 ​ 10,124 Thereafter ​ 42,163 Total ​ $ 94,725 ​ The Company recorded no impairment charges related to identifiable intangible assets during the three and nine months ended September 30, 2020 and 2019.

Fair Value of Assets and Liabil

Fair Value of Assets and Liabilities	9 Months Ended
	Sep. 30, 2020
Fair Value of Assets and Liabilities
Fair Value of Assets and Liabilities	(6) Fair Value of Assets and Liabilities FASB ASC Topic 820, Fair Value Measurements and Disclosures ​ ​ ​ Level input ​ Input Definition Level 1 ​ Inputs are unadjusted, quoted prices for identical assets or liabilities in active markets at the measurement date. Level 2 ​ Inputs, other than quoted prices included in Level 1 that are observable for the asset or liability through corroboration with market data at the measurement date. Level 3 ​ Unobservable inputs that reflect management’s best estimate of what market participants would use in pricing the asset or liability at the measurement date. ​ The following table presents the valuation of the Company’s financial assets and liabilities as of September 30, 2020 and December 31, 2019 measured at fair value on a recurring basis. These estimates are not necessarily indicative of the amounts the Company could ultimately realize. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ (in thousands) Level 1 Level 2 Level 3 Fair Value September 30, 2020 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Assets ​ ​ ​ ​ Money market accounts ​ $ 198,919 ​ $ — ​ $ — ​ $ 198,919 Total assets measured at fair value ​ $ 198,919 ​ $ — ​ $ — ​ $ 198,919 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Liabilities ​ ​ ​ ​ Acquisition-related contingent consideration-short term ​ $ — ​ $ — ​ $ 3,789 ​ $ 3,789 Acquisition-related contingent consideration-long term ​ — ​ — ​ 13,346 ​ 13,346 Interest rate swap agreements-short term ​ ​ — ​ ​ 5,890 ​ ​ — ​ ​ 5,890 Interest rate swap agreements-long term ​ — ​ 11,877 ​ — ​ 11,877 Total liabilities measured at fair value ​ $ — ​ $ 17,767 ​ $ 17,135 ​ $ 34,902 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ (in thousands) Level 1 Level 2 Level 3 Fair Value December 31, 2019 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Assets ​ ​ ​ ​ Money market accounts ​ $ 54,015 ​ $ — ​ $ — ​ $ 54,015 Total assets measured at fair value ​ $ 54,015 ​ $ — ​ $ — ​ $ 54,015 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Liabilities ​ ​ ​ ​ Acquisition-related contingent consideration-short term ​ $ — ​ $ — ​ $ 4,825 ​ $ 4,825 Acquisition-related contingent consideration-long term ​ — ​ — ​ 9,900 ​ 9,900 Interest rate swap agreements-short term ​ ​ — ​ ​ 2,157 ​ ​ — ​ ​ 2,157 Interest rate swap agreements-long term ​ — ​ 6,182 ​ — ​ 6,182 Total liabilities measured at fair value ​ $ — ​ $ 8,339 ​ $ 14,725 ​ $ 23,064 ​ Interest Rate Swaps The Company recognizes its interest rate swaps as either assets or liabilities in the accompanying consolidated balance sheets at fair value. The valuation of these derivative instruments is determined using widely accepted valuation techniques, including discounted cash flow analysis on the expected cash flows of each derivative. This analysis reflects the contractual terms of the derivatives, including the period to maturity, and uses observable market-based inputs, including interest rate curves and implied volatilities. The Company’s interest rate swaps held as of September 30, 2020 and December 31, 2019 were classified as Level 2 of the fair value hierarchy. Refer to Note 7, Derivative Instruments and Hedging Activities Contingent Consideration The Company estimates the fair value of acquisition-related contingent consideration liabilities by applying the income approach using a probability-weighted discounted cash flow model. This fair value measurement is based on significant inputs not observed in the market and thus represents a Level 3 measurement. Level 3 instruments are valued based on unobservable inputs that are supported by little or no market activity and reflect the Company’s own assumptions in measuring fair value. At September 30, 2020, contingent consideration liabilities of $3.8 million and $13.3. million were included in other current liabilities and other long-term liabilities, respectively, in the accompanying consolidated balance sheets. At December 31, 2019, contingent consideration liabilities of $4.8 million and $9.9 million were included in other current liabilities and other long-term liabilities, respectively, in the accompanying consolidated balance sheets. A reconciliation of the Company’s contingent consideration liabilities related to acquisitions for the nine months ended September 30, 2020 and 2019 is as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Nine Months Ended September 30, 2020 ​ Beginning Balance Additions Payments Change in Fair Value Other activity Ending Balance Contingent consideration - Level 3 liabilities ​ $ 14,725 ​ $ 6,464 ​ $ (1,200) ​ $ (2,900) ​ $ 46 ​ $ 17,135 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Nine Months Ended September 30, 2019 ​ Beginning Balance Additions Payments Change in Fair Value Other activity Ending Balance Contingent consideration - Level 3 liabilities ​ $ 15,250 ​ $ 6,425 ​ $ (13,000) ​ $ (625) $ — ​ $ 8,050 ​ The following table presents the Company’s hierarchy for non-financial assets measured at fair value on a non-recurring basis (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, ​ December 31, ​ ​ 2020 2019 Assets: ​ ​ ​ Goodwill (Level 3) ​ $ 810,480 ​ $ 266,791 Identifiable intangible assets, net (Level 3) ​ ​ 94,725 ​ ​ — ​ The fair value allocation related to the Company’s acquisitions are determined using a discounted cash flow approach, or a replacement cost approach, which are based on significant unobservable inputs (Level 3). The Company estimates the fair value using the income approach (which is a discounted cash flow technique) or the cost approach. These valuation methods required management to make various assumptions, including, but not limited to, future profitability, cash flows, replacement costs, and discount rates. The Company’s estimates are based upon historical trends, management’s knowledge and experience and overall economic factors, including projections of future earnings potential. ​ Developing discounted future cash flows in applying the income approach requires the Company to evaluate its intermediate to longer-term strategies, including, but not limited to, estimates of revenue growth, operating margins, capital requirements, inflation and working capital management. The development of appropriate rates to discount the estimated future cash flows requires the selection of risk premiums, which can materially impact the present value of future cash flows. ​ The Company estimated the fair value of acquired intangible assets using discounted cash flow techniques that included an estimate of future cash flows, consistent with overall cash flow projections used to determine the purchase price paid to acquire the business, discounted at a rate of return that reflects the relative risk of the cash flows. The Company estimated the fair value of certain acquired intangible assets based on the cost approach using estimated costs consistent with historical experience. The Company believes the estimates and assumptions used in the valuation methods are reasonable.

Derivative Instruments and Hedg

Derivative Instruments and Hedging Activities	9 Months Ended
	Sep. 30, 2020
Derivative Instruments and Hedging Activities
Derivative Instruments and Hedging Activities	(7) Derivative Instruments and Hedging Activities The Company records all derivatives on its consolidated balance sheet at fair value. As of September 30, 2020 and December 31, 2019, the Company had outstanding interest rate derivatives with third parties in which the Company pays a fixed interest rate and receives a rate equal to the one-month LIBOR. The notional amount associated with the swap agreements was $250 million as of September 30, 2020 and December 31, 2019 and have maturity dates at certain dates through March 2024. Prior to August 22, 2019, the interest rate swap agreements were not designated as cash flow hedging instruments for accounting purposes and accordingly changes in fair value of the interest rate swap agreements were recorded in earnings. On August 22, 2019, the Company designated its swaps as effective cash flow hedges of interest rate risk. Accordingly, subsequent to August 22, 2019, changes in the fair value of the interest rate swaps are recorded as a component of accumulated other comprehensive income (loss) within stockholders’ equity and subsequently reclassified into interest expense in the same period during which the hedged transaction affects earnings. The table below presents the fair value of the Company’s derivatives designated as hedging instruments as well as their classification in the consolidated balance sheets at September 30, 2020 and December 31, 2019 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, 2020 ​ December 31, 2019 ​ ​ Balance Sheet Location ​ Asset (Liability) Interest rate swap agreements ​ Other current liabilities ​ $ (5,890) ​ $ (2,157) Interest rate swap agreements ​ Other long-term liabilities ​ (11,877) ​ (6,182) Total ​ ​ ​ $ (17,767) ​ $ (8,339) ​ During the three and nine months ended September 30, 2020, as a result of the effect of cash flow hedge accounting, the Company recognized income of $1.6 million and a loss of $9.4 million, respectively, in other comprehensive income (loss). In addition, during the three and nine months ended September 30, 2020, $0.7 million and $2.1 million, respectively, was reclassified from other comprehensive income (loss) and recognized as a reduction to interest expense, net, in the accompanying consolidated statements of operations. During each of the three and nine months ended September 30, 2019, as a result of the effect of cash flow hedge accounting, the Company recognized income of $1.1 million in other comprehensive income (loss). In addition, during each of the three and nine months ended September 30, 2019, $0.2 million was reclassified from other comprehensive income (loss) and recognized as a reduction to interest expense, net, in the accompanying consolidated statements of operations. During the three and nine months ended September 30, 2019, as a result of the effect of the Company’s derivative financial instruments that were not designated as hedging instruments, the Company recognized $2.9 million and $12.4 million, respectively, in interest expense, net in the accompanying consolidated statements of operations.

Accounts Payable and Accrued Ex

Accounts Payable and Accrued Expenses	9 Months Ended
	Sep. 30, 2020
Accounts Payable and Accrued Expenses
Accounts Payable and Accrued Expenses	(8) Accounts Payable and Accrued Expenses Accounts payable and accrued expenses as of September 30, 2020 and December 31, 2019 consisted of the following (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, ​ December 31, ​ ​ 2020 ​ 2019 Accounts payable ​ $ 144,804 $ 79,237 Employee related accruals ​ 17,550 ​ 12,320 Accrued interest ​ 10,294 ​ 4,022 Other ​ 19,689 ​ 7,149 Total ​ $ 192,337 ​ $ 102,728 ​

Debt

Debt	9 Months Ended
	Sep. 30, 2020
Debt
Debt	(9) Debt The following is a summary of long term-debt as of September 30, 2020 and December 31, 2019 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, ​ December 31, ​ ​ 2020 ​ 2019 Secured term loans ​ $ 250,000 $ 246,250 Revolving credit facility ​ ​ — ​ ​ 12,000 Senior unsecured notes ​ ​ 350,000 ​ ​ — Note payable ​ 143,500 ​ 143,500 Other ​ 666 ​ 1,725 Unamortized discount on senior unsecured notes ​ ​ (5,997) ​ ​ — Unamortized deferred financing fees ​ (6,960) ​ (6,642) ​ ​ 731,209 ​ 396,833 Current portion ​ (8,479) ​ (1,721) Long-term portion ​ $ 722,730 ​ $ 395,112 ​ In July 2020, the Company refinanced its debt borrowings and entered into a new credit agreement with a new bank group (the Credit Agreement). The Credit Agreement consists of a $250 million term loan (the Term Loan) and $200 million in commitments for revolving credit loans with a $15 million letter of credit sublimit (the Revolver), both with maturities in July 2025. The amount borrowed under the Term Loan bears interest quarterly at variable rates based upon the sum of (a) the Adjusted LIBOR Rate (subject to a floor) equal to the LIBOR (as defined in the Credit Agreement) for the applicable interest period, plus (b) an applicable margin ranging from 2.50% to 3.75% per annum based on the Consolidated Total Leverage Ratio (as defined in the Credit Agreement). The Revolver carries a commitment fee during the term of the Credit Agreement ranging from 0.25% to 0.50% per annum of the average daily undrawn portion of the Revolver based on the Consolidated Total Leverage Ratio. In connection with the Credit Agreement, the Company paid deferred financing costs of $2.7 million; such costs are being amortized over the term of the related debt and is included in interest expense, net in the accompanying consolidated statements of operations. ​ Under the Credit Agreement, the Company is subject to several restrictive covenants that, among other things, impose operating and financial restrictions on the Company. Financial covenants include a Consolidated Total Leverage Ratio and a Consolidated Fixed Charge Coverage Ratio, as defined in the Credit Agreement. The Credit Agreement also contains certain customary events of default, including, among other things, failure to make payments when due thereunder, failure to observe or perform certain covenants, and non-compliance with healthcare laws. Any borrowing under the Credit Agreement may be repaid, in whole or in part, at any time and from time to time without premium or penalty, other than customary breakage costs, and any amounts repaid may be reborrowed. Mandatory prepayments are required in connection with the disposition of assets to the extent not reinvested, unpermitted debt transactions, and excess cash flow, as defined in the Credit Agreement, if certain leverage tests are not met. The Company was in compliance with all debt covenants as of September 30, 2020. ​ In March 2019, the Company entered into several agreements, amendments and new credit facilities (herein after referred to as the March 2019 Recapitalization Transactions). The March 2019 Recapitalization Transactions included $425 million in new credit facilities, which consisted of a $300 million Initial Term Loan, $50 million Delayed Draw Term Loan, and $75 million Revolving Credit Facility, collectively referred to herein as the 2019 Credit Facility. Amounts borrowed under the 2019 Credit Facility bore interest quarterly at variable rates based upon the sum of (a) the LIBOR Rate for such interest period, plus (b) an applicable margin based upon the Company’s Consolidated Total Leverage Ratio (as defined in the Credit Agreement). In July 2020, the Company amended the 2019 Credit Facility and borrowed $216.3 million; such proceeds were used to partially fund an acquisition. In connection with this amendment, the Company paid deferred financing costs of $1.8 million. The Company used a portion of the net proceeds from the borrowings under the Term Loan and the issuance of the Senior Unsecured Notes (see discussion below) to fully repay the outstanding principal balances under the 2019 Credit Facility totaling $523.9 million, and to pay the related accrued interest, fees and expenses. Further, in connection with executing the Credit Agreement discussed above, the Company wrote off unamortized deferred financing costs of $5.3 million related to the 2019 Credit Facility, which is included in loss on extinguishment of debt in the accompanying consolidated statements of operations for the three and nine months ended September 30, 2020. ​ The proceeds from the March 2019 Recapitalization Transactions were used to (1) repay existing amounts outstanding under the Company’s then existing credit facility of $151.9 million, (2) pay transaction costs, fees and expenses related to the consummation of the transactions contemplated under the agreement (see Note and Unit Purchase Agreement discussed below), (3) pay a $250 million distribution to AdaptHealth Holdings’ members, and (4) redeem certain members’ interests, including the cumulative preferred dividends, for $3.7 million. In addition, the Company paid deferred financing costs of $9.0 million; amortization of such costs is included in interest expense, net in the accompanying consolidated statements of operations. Further, the Company wrote off unamortized deferred financing costs of $2.1 million, which is included in loss on extinguishment of debt in the accompanying consolidated statements of operations for the nine months ended September 30, 2019. ​ Secured Term Loans ​ The borrowing under the Term Loan requires quarterly principal repayments of $1.6 million beginning September 30, 2020 through June 30, 2022, increasing to $3.1 million beginning September 30, 2022 through June 30, 2025, and the unpaid principal balance is due at maturity in July 2025. At September 30, 2020, there was $250.0 million outstanding under the Term Loan. The interest rate under the Term Loan was 3.69% at September 30, 2020. ​ Revolving Credit Facility ​ No amounts have been borrowed under the Revolver. Borrowings under the Revolver may be used for working capital and other general corporate purposes, including for capital expenditures and acquisitions permitted under the Credit Agreement. After consideration of stand-by letters of credit outstanding of $4.0 million, the remaining maximum borrowings available pursuant to the Revolver were $196.0 million at September 30, 2020. ​ Senior Unsecured Notes ​ In July 2020, the Company issued $350.0 million aggregate principal amount of 6.125% senior unsecured notes due 2028 (the Notes) and received proceeds of $343.9 million. The discount on the Notes of $6.1 million is being amortized over the term of the related debt and is included in interest expense, net in the accompanying consolidated statements of operations. The Notes will mature on August 1, 2028. Interest on the Notes will be payable on February 1st and August 1st of each year, beginning on February 1, 2021. The Notes will be redeemable at the Company’s option, in whole or in part, at any time on or after August 1, 2023, and the redemption price for the Notes if redeemed during the 12 months beginning (i) August 1, 2023 is 103.063%, (ii) August 1, 2024 is 102.042%, (iii) August 1, 2025 is 101.021% and (iv) August 1, 2026 and thereafter is 100.000%, in each case together with accrued and unpaid interest. The Company may also redeem some or all of the Notes before August 1, 2023 at a redemption price of 100% of the principal amount of the Notes, plus a “make-whole” premium, together with accrued and unpaid interest. In addition, the Company may redeem up to 40% of the original aggregate principal amount of the Notes before August 1, 2023 with the proceeds from certain equity offerings at a redemption price equal to 106.125% of the principal amount of the Notes, together with accrued and unpaid interest. Furthermore, the Company may be required to make an offer to purchase the Notes upon the sale of certain assets or upon specific kinds of changes of control. In connection with the Notes, the Company paid deferred financing costs of $2.3 million; such costs are being amortized over the term of the related debt and is included in interest expense, net in the accompanying consolidated statements of operations. ​ Note Payable ​ In connection with the March 2019 Recapitalization Transactions, the Company signed a Note and Unit Purchase Agreement with an investor. Pursuant to the agreement, the Company issued a promissory note with a principal amount of $100 million (the Promissory Note) and the Company also received proceeds of $20 million for the purchase of members’ interests. In connection with the transactions completed as part of the Business Combination, the Promissory Note was replaced with a new amended and restated promissory note with a principal amount of $100 million, and the investor converted certain of its members’ interests to a $43.5 million promissory note. The new $100 million promissory note, together with the $43.5 million promissory note, are collectively referred to herein as the New Promissory Note. The outstanding principal balance under the New Promissory Note is due on the tenth anniversary of the closing date of the Business Combination and bears interest at the following rates (a) for the period starting on the closing date and ending on the seventh anniversary, a rate of 12% per annum, and (b) for the period starting on the day after the seventh anniversary of the closing date and ending on the maturity date, a rate equal to the greater of (i) 15% per annum or (ii) the twelve-month LIBOR plus 12% per annum. Under the New Promissory Note, the Company had the option to pay 6% of the interest in cash and 6% Payment in Kind (PIK). The Company elected to pay the PIK interest in cash during all periods. At any time following September 20, 2021, the Company may prepay, in whole (but not in part), the outstanding principal amount, together with all accrued and unpaid interest thereon. If the Company elects to prepay the New Promissory Note prior to September 21, 2023, then the amount due and payable shall be subject to a make-whole premium equal to a percentage of the total amount of outstanding principal and accrued interest through the date of such prepayment. The make-whole premium percentage during the period from September 21, 2021 through September 20, 2022 is 10%, and from September 21, 2022 through September 20, 2023 is 5%. In addition, if the Company desires to consummate any Qualified Acquisition (as defined in the New Promissory Note) without the consent of the investor, the Company may proceed with such acquisition if the New Promissory Note is prepaid at the closing of such acquisition. If such acquisition occurs prior to September 21, 2023, then the amount due and payable shall be subject to a make-whole premium equal to a percentage of the total amount of outstanding principal and accrued interest through the date of such prepayment. The make-whole premium percentage during the period from September 21, 2020 through September 20, 2021 is 15%, from September 21, 2021 through September 20, 2022 is 10%, and from September 21, 2022 through September 20, 2023 is 5%. Further, if a Sale of the Company (as defined in the New Promissory Note) occurs prior to the maturity date, then, effective immediately prior to and contingent upon the consummation of such transaction, the outstanding principal, together with all accrued and unpaid interest, shall be due and payable. If such transaction occurs prior to September 21, 2023, then the amount due and payable shall be subject to a make-whole premium equal to a percentage of the total amount of outstanding principal and accrued interest through the date of such prepayment. The make-whole premium percentage during the period from November 8, 2019 through September 20, 2022 is 10%, and from September 21, 2022 through September 20, 2023 is 5%. ​ In connection with the Business Combination, the investor generated taxable income and a current federal and state income tax liability of $5.9 million on the exchange of its members’ interests. Under the terms of the Merger Agreement, all investors indemnified the Company for all taxes attributable to periods prior to or on the closing date of the Business Combination. Accordingly, the Company recorded an indemnification asset of such amount, included in Prepaid and other current assets, and a corresponding current liability included in Other liabilities, in the accompanying consolidated balance sheets as of and December 31, 2019. This amount is no longer outstanding as of September 30, 2020. ​ In May 2020, the Company and the investor entered into a Put/Call Option and Consent Agreement (the Put/Call Agreement), pursuant to which certain put and call rights were granted to the parties with respect to shares of Class A Common Stock, shares of Class B Common Stock, and common units of AdaptHealth Holdings (each such common unit, together with one share of Class B Common Stock, a Consideration Unit) held by the investor. Pursuant to the Put/Call Agreement, during the period from the closing of the Company’s acquisition of Solara to October 31, 2020, which was subsequently extended to December 31, 2020 pursuant to an amendment to the Put/Call Agreement executed by the parties in October 2020 (the Option Period), the investor may require the Company to purchase up to 1,898,967 shares of Class A Common Stock and/or Consideration Units held by the investor (such shares of Class A Common Stock and Consideration Units, collectively, Interests) at a price per share of Class A Common Stock or per Consideration Unit equal to the greater of (x) $14.50 and (y) 85% of the 30-day volume-weighted average price per share of the Company’s Class A Common Stock on the date the exercise notice is delivered. During the Option Period, the Company may also require the investor to sell up to 1,898,967 of the Interests held by the investor to the Company at a price per share of Class A Common Stock or per Consideration Unit of $15.76. In addition, under the Put/Call Agreement, the investor waived certain consent rights under the New Promissory Note, and the Company irrevocably agreed to pay all PIK interest payable under the New Promissory Note following the closing of the acquisition of Solara in cash rather than through an increase in the principal amount of the notes. In connection with the Put/Call Agreement, the Company recorded a decrease to additional paid-in capital and accumulated deficit of $2.7 million, representing the estimated net fair value of the related call and put option.

Stockholders' Equity

Stockholders' Equity	9 Months Ended
	Sep. 30, 2020
Stockholders' Equity
Stockholders' Equity	(10) Stockholders' Equity The Closing of the Business Combination occurred on November 8, 2019, refer to Note 3, Significant Transactions In July 2020, the Company received gross proceeds of $190.0 million in connection with the sale of 10.9 million shares of Class A Common Stock and 39,706 shares of Series A Preferred Stock pursuant to a private placement transaction. In addition, in July 2020, the Company received gross proceeds of $35.0 million in connection with the sale of 35,000 shares of Series B-2 Preferred Stock pursuant to a private placement transaction. In connection with these transactions, the Company paid offering costs of $1.6 million. In September 2020, the 39,706 shares of Series A Preferred Stock were converted into 2.9 million shares of Class A Common Stock. In addition, in September 2020, the 35,000 shares of Series B-2 Preferred Stock were converted into 25,454.55 shares of Series B-1 Preferred Stock (see below for a discussion of the Company’s outstanding Series B-1 Preferred Stock). ​ In July 2020, the Company issued 9.2 million shares of Class A Common Stock at a price of $15.50 per share pursuant to an underwritten public offering and received gross proceeds of $142.6 million. In connection with this transaction, the Company paid offering costs, inclusive of the underwriting discount, of $9.6 million. ​ Preferred Stock In June 2020, the Company entered into an exchange agreement (the Exchange Agreement) with an investor pursuant to which the investor exchanged 15,810,547 shares of the Company’s Class A Common Stock for 158,105.47 shares of Series B-1 Preferred Stock, par value $0.0001 per share. The Series B-1 Preferred Stock liquidation preference is limited to its par value of $0.0001 per share. The Series B-1 Preferred Stock will participate equally and ratably on an as-converted basis with the holders of Class A Common Stock in all cash dividends paid on the Class A Common Stock. The Series B-1 Preferred Stock is non-voting. The holder may convert each share of Series B-1 Preferred Stock into 100 shares of Class A Common Stock (subject to certain anti-dilution adjustments) at its election, except to the extent that, following such conversion, the number of shares of Class A Common Stock held by such holder and its affiliates exceed 4.9% of the outstanding Class A Common Stock of the Company. Warrants At the Closing of the Business Combination, the Company had 12.7 million warrants outstanding. Each warrant is exercisable into one share of Class A Common Stock at a price of $11.50 per share. The exercise price and number of shares of Class A Common Stock issuable upon exercise of the warrants may be adjusted in certain circumstances including in the event of a share dividend, or recapitalization, reorganization, merger or consolidation. However, the warrants will not be adjusted for the issuance of common stock at a price below its exercise price. During the nine months ended September 30, 2020, 6.2 million warrants were exercised in cashless transactions resulting in the issuance of 2.0 million shares of Class A Common Stock, which included the redemption of Public Warrants (see below). In addition, during the nine months ended September 30, 2020, 2.1 million warrants were exercised for cash proceeds of $24.5 million, resulting in the issuance of 2.1 million shares of Class A Common Stock. As of September 30, 2020, the Company had 4.3 million warrants outstanding. Redemption of Public Warrants On August 4, 2020, the Company announced its intention to redeem all of its outstanding public warrants (the Public Warrants) to purchase shares of the Company’s Class A Common Stock, that were issued under the Warrant Agreement, dated February 15, 2018 (the Warrant Agreement), by and between the Company and Continental Stock Transfer & Trust Company, as warrant agent (the Warrant Agent), as part of the units sold in the Company’s initial public offering (the IPO), for a redemption price of $0.01 per Public Warrant (the Redemption Price), that remained outstanding on September 2, 2020 (the Redemption Date). Warrants to purchase common stock that were issued under the Warrant Agreement in a private placement simultaneously with the IPO and still held by the initial holders thereof or their permitted transferees were not subject to this redemption. ​ Under the terms of the Warrant Agreement, the Company was entitled to redeem all of the outstanding Public Warrants if the last sales price of the Company’s Class A Common Stock was at least $18.00 per share on each of twenty trading days within any thirty-day trading period ending on the third trading day prior to the date on which a notice of redemption is given. At the direction of the Company, the Warrant Agent delivered a notice of redemption to each of the registered holders of the outstanding Public Warrants. ​ In addition, in accordance with the Warrant Agreement, the Company elected to require that, upon delivery of the notice of redemption, all Public Warrants were to be exercised only on a “cashless basis.” Accordingly, holders were no longer able to exercise Public Warrants and receive common stock in exchange for payment in cash of the $11.50 per warrant exercise price. Instead, a holder exercising a Public Warrant was deemed to pay the $11.50 per warrant exercise price by the surrender of 0.6144 of a share of common stock (such fraction determined as described below) that such holder would have been entitled to receive upon a cash exercise of a Public Warrant. Accordingly, by virtue of the cashless exercise of the Public Warrants, exercising warrant holders received 0.3856 of a share of common Stock for each Public Warrant surrendered for exercise. Any Public Warrants that remained unexercised on the Redemption Date were voided and no longer exercisable, and the holders will have no rights with respect to those Public Warrants, except to receive the Redemption Price. ​ The number of shares of Class A Common Stock that each exercising warrant holder received by virtue of the cashless exercise (instead of paying the $11.50 per Public Warrant cash exercise price) was calculated in accordance with the terms of the Warrant Agreement and was equal to the quotient obtained by dividing (x) the product of the number of shares underlying the Public Warrants held by such warrant holder, multiplied by the difference between $18.7175, the average last sale price of the Company’s Class A Common Stock for the ten trading days ending on July 29, 2020, the third trading day prior to the date of the redemption notice (the Fair Market Value) and $11.50, by (y) the Fair Market Value. If any holder of Public Warrants would, after taking into account all of such holder’s Public Warrants exercised at one time, be entitled to receive a fractional interest in a share of common stock, the number of shares the holder was entitled to receive was rounded down to the nearest whole number of shares. During the nine months ended September 30, 2020, 2.3 million Public Warrants were redeemed resulting in the issuance of 0.9 million shares of Class A Common Stock. As a result of these transactions, there are no Public Warrants outstanding. Contingent Consideration Shares Pursuant to the Merger Agreement, the former owners of AdaptHealth Holdings who received Class B Common Stock in connection with the Business Combination are entitled to receive an equity classified earn-out consideration to be paid in the form of New AdaptHealth Units (and a corresponding number of shares of Class B Common Stock) and the former owners of AdaptHealth Holdings who received Class A Common Stock in connection with the Business Combination are entitled to receive earn-out consideration to be paid in the form of Class A Common Stock, if the average price of the Company’s Class A Common Stock for the month of December prior to each measurement date equals or exceeds certain hurdles set forth in the Merger Agreement. The former owners of AdaptHealth Holdings can potentially receive up to an additional 1.0 million shares at December 31, 2020, 2021 and 2022 (each a measurement date) and such average stock price hurdles are $15, $18 and $22 at each measurement date, respectively, for a total of 3.0 million shares, as a part of the earn-out consideration. Equity-based Compensation On November 7, 2019, the stockholders of the Company approved the AdaptHealth Corp. 2019 Stock Incentive Plan (the 2019 Plan), effective upon closing of the Business Combination. In connection with the 2019 Plan, the Company provides equity-based compensation to attract and retain employees while also aligning employees’ interest with the interests of its stockholders. The 2019 Plan permits the grant of various equity-based awards to selected employees and directors. The 2019 Plan permits the grant of up to 8.0 million shares of Class A Common Stock, subject to certain adjustments and limitations. During the three months ended September 30, 2020, the Company recorded equity-based compensation expense of $5.5 million, of which $3.7 and $1.8 million was included in general and administrative expenses and cost of net revenue, respectively, in the accompanying consolidated statement of operations. During the nine months ended September 30, 2020, the Company recorded equity-based compensation expense of $11.0 million, of which $7.0 and $4.0 million was included in general and administrative expenses and cost of net revenue, respectively, in the accompanying consolidated statement of operations. During the three and nine months ended September 30, 2019, the Company recorded equity-based compensation expense of $0.4 million and $5.8 million, respectively, which is included in general and administrative expenses in the accompanying consolidated statements of operations. The expense during the nine months ended September 30, 2019 included $4.9 million in connection with the acceleration of vesting of certain of the 2018 Incentive Units and the modification of such awards discussed below. At September 30, 2020, there was $32.8 million of unrecognized compensation expense related to equity-based compensation awards, which is expected to be recognized over a weighted-average term of 2.9 years. At September 30, 2020, 1.5 million shares of the Company’s Class A Common Stock are available for issuance under the 2019 Plan. In August 2020, the Company granted 10,755 shares of Class A Common Stock to certain newly hired employees. The fair value of these immediately vested shares was $0.2 million and was recognized as compensation cost during the three and nine months ended September 30, 2020. In May 2020, the Company granted 11,625 shares of Class A Common Stock to certain newly hired employees. The fair value of these immediately vested shares was $0.2 million and was recognized as compensation cost during the nine months ended September 30, 2020. In addition, in May 2020, the Company granted 16,329 shares of Class A Common Stock to certain frontline patient-facing employees in connection with a Covid-19 retention bonus program. The fair value of these immediately vested shares was $0.2 million and was recognized as compensation cost during the nine months ended September 30, 2020. Stock Options In November 2019, the Company granted 3,416,666 options to purchase shares of Class A Common Stock of the Company to certain executive officers that have an exercise price of $11.50 per share. The grant-date fair value of the awards, using a Black-Scholes option pricing model, was $7.2 million and is being recognized as expense on a straight-line basis over the employees’ requisite service period subject to management’s estimation of the probability of vesting of such awards. In April 2020, the Company granted 47,335 options to purchase shares of Class A Common Stock of the Company to an employee that have an exercise price of $16.25 per share. The grant-date fair value of the awards, using a Black-Scholes option pricing model, was $0.3 million and is being recognized as expense on a straight-line basis over the employees’ requisite service period subject to management’s estimation of the probability of vesting of such awards. A portion of all options outstanding are eligible to vest on December 31, 2020, 2021 and 2022 based on defined performance conditions, subject to the employees’ continuous employment through the applicable vesting date. The Company has no other options outstanding as of September 30, 2020. The assumptions used to determine the grant-date fair value of the stock options granted during the nine months ended September 30, 2020 were as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ Expected volatility 40.7 % Risk-free interest rate 0.4 % Expected term 6.0 years Dividend yield ​ N/A ​ ​ Restricted Stock During the three months ended September 30, 2020, the Company granted 450,369 shares of restricted stock to various employees, which primarily vest ratably over the three and four-year periods following the grant dates, subject to the employees’ continuous employment through the applicable vesting date. The grant-date fair value of these awards was $9.0 million which is being recognized as expense on a straight-line basis over the employees’ requisite service period. During the three months ended September 30, 2020, the Company granted 840,219 shares of restricted stock to various employees which vest based on certain performance conditions, subject to the employees’ continuous employment through the applicable vesting date. The total grant-date fair value of these awards was $16.1 million which is being recognized as expense on a straight-line basis over the employee’s requisite service period subject to management’s estimation of the probability of vesting of such awards. During the three months ended September 30, 2020, the Company granted 37,198 shares of restricted stock to its non-employee directors, which vest immediately prior to the Company’s 2021 annual stockholders meeting. The grant-date fair value of these awards was $0.8 million which is being recognized as expense on a straight-line basis over the applicable vesting period During the three months ended June 30, 2020, the Company granted 77,896 shares of restricted stock to certain employees, which vest over the four-year period following the grant date, subject to the employees’ continuous employment through the applicable vesting date. The grant-date fair value of these awards was $1.2 million which is being recognized as expense on a straight-line basis over the employees’ requisite service period. In April 2020, the Company granted 20,656 shares of restricted stock to an employee. On each of December 31, 2020, 2021 and 2022, one -third of the shares are eligible to vest based on the cumulative annual growth rate of the Company’s stock during the ten trading days preceding the vesting date (which is considered a market condition), subject to the employee’s continuous employment with the Company through such vesting date. The grant-date fair value of the awards, using a Monte Carlo simulation analysis, was $0.3 million which is being recognized as expense on a straight-line basis over the employee’s requisite service period. In March 2020, the Company granted 300,000 shares of restricted stock to an employee in conjunction with an acquisition. Of the total shares granted, 250,000 are eligible to vest based on certain performance conditions, subject to the employee's continuous employment through the applicable vesting date. The remaining 50,000 shares vest 25% annually on December 31, 2020 through 2023, subject to the employee's continuous employment through the applicable vesting date. The total grant-date fair value of the award was $4.9 million which is being recognized as expense on a straight-line basis over the employee’s requisite service period subject to management’s estimation of the probability of vesting of such awards (as it relates to the performance-based awards). In March 2020, the Company granted 323,510 shares of restricted stock to various employees. Of the total shares granted, 15,417 shares vested on the grant date, and the remaining shares vest 25% on each anniversary of the grant dates, subject to the employees’ continuous employment through the applicable vesting date. The grant-date fair value of the awards was $5.3 million, of which $0.3 million was recognized as expense on the grant date and $5.0 million is being recognized as expense on a straight-line basis over the employees’ requisite service period. Activity related to the Company’s non-vested restricted stock grants for the nine months ended September 30, 2020 is presented below (in thousands, except per share data): ​ ​ ​ ​ ​ ​ ​ ​ ​ Number of Shares of ​ ​ Weighted-Average Grant Date ​ ​ Restricted Stock ​ Fair Value per Share Non-vested balance at January 1, 2020 ​ 901 $ 5.83 Granted ​ 2,050 ​ $ 18.32 Vested ​ (44) ​ $ 12.04 Forfeited ​ (39) ​ $ 10.85 Non-vested balance at September 30, 2020 ​ 2,868 ​ $ 14.54 ​ Incentive Units AdaptHealth Holdings granted Incentive Units in June 2019 (the 2019 Incentive Units) and in April 2018 (the 2018 Incentive Units) to certain members of management. With respect to the 2019 Incentive Units, 50% of the awards vest in equal annual installments on each of the first four anniversaries of the Vesting Commencement Date as defined in the agreements (May 20, 2019). The remaining 50% had vesting terms based upon a performance condition. In connection with the Business Combination, the vesting condition for this portion of the 2019 Incentive Units was changed to vest quarterly during the one

Earnings Per Share

Earnings Per Share	9 Months Ended
	Sep. 30, 2020
Earnings per share
Earnings Per Share	(11) Earnings Per Share The Business Combination was accounted for as a reverse recapitalization by which AdaptHealth Holdings issued stock for the net assets of the Company accompanied by a recapitalization. Earnings per share (EPS) has been recast for all historical periods to reflect the Company’s capital structure for all comparative periods. EPS is computed by dividing net income (loss) by the weighted average number of common shares outstanding during the period on a basic and diluted basis. The Company calculates diluted earnings per share using the more dilutive of the treasury stock method and the two-class method after giving effect to all potential dilutive common stock. The Company’s potentially dilutive securities include potential common shares related to outstanding warrants (Note 10), Contingent Consideration Shares (Note 10), unvested restricted stock and outstanding preferred stock (Note 10). Diluted EPS considers the impact of potentially dilutive securities except when the potential common shares have an antidilutive effect. The Company’s outstanding preferred stock are considered participating securities, thus requiring the two-class method of computing EPS. Calculation of EPS under the two-class method excludes from the numerator any dividends paid or owed on participating securities and any undistributed earnings considered to be attributable to participating securities. The related participating securities are similarly excluded from the denominator. Computations of basic and diluted earnings per share were as follows (in thousands, except per share data): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended September 30, ​ Nine Months Ended September 30, ​ ​ 2020 ​ 2019 2020 ​ 2019 Numerator ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net income (loss) attributable to AdaptHealth Corp. ​ $ (2,489) ​ $ (3,686) ​ $ 1,386 ​ $ (11,570) Less: Earnings allocated to participating securities (1) (2) ​ ​ — ​ ​ — ​ ​ 184 ​ ​ — Basic and diluted earnings - Net income (loss) attributable to AdaptHealth Corp. after allocation to participating securities ​ $ (2,489) ​ $ (3,686) ​ $ 1,202 ​ $ (11,570) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Denominator (1) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Basic weighted-average common shares outstanding ​ ​ 57,372 ​ ​ 21,721 ​ ​ 47,986 ​ ​ 19,130 Add: Warrants (See Note 10) ​ ​ — ​ ​ — ​ ​ 1,438 ​ ​ — Add: Contingent Consideration Shares (See Note 10) ​ ​ — ​ ​ — ​ ​ 700 ​ ​ — Add: Unvested restricted stock ​ ​ — ​ ​ — ​ ​ 724 ​ ​ — Diluted weighted-average common shares outstanding (2) ​ ​ 57,372 ​ ​ 21,721 ​ ​ 50,848 ​ ​ 19,130 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Basic earnings (loss) per share ​ $ (0.04) ​ $ (0.17) ​ $ 0.03 ​ $ (0.60) Diluted earnings (loss) per share ​ $ (0.04) ​ $ (0.17) ​ $ 0.02 ​ $ (0.60) ​ (1) The Company's preferred stock are considered participating securities. Calculation of EPS under the two-class method excludes from the numerator any dividends paid or owed on participating securities and any undistributed earnings considered to be attributable to participating securities. The related participating securities are similarly excluded from the denominator. There were participating securities outstanding for the three and nine months ended September 30, 2020. There were no participating securities outstanding for the three and nine months ended September 30, 2019. (2) There were no earnings allocated to the participating securities for the three months ended September 30, 2020 and the number of shares in the diluted loss per share calculation for the three months ended September 30, 2020 and the three and nine months ended September 30, 2019 are the same as the number of shares used in the basic loss per share calculation due to the net loss in those periods. . ​

Leases

Leases	9 Months Ended
	Sep. 30, 2020
Lease Commitments
Lease Commitments	(12) Leases Capital Leases ​ The Company has acquired patient medical equipment and supplies, and office equipment through multiple capital leases. The capital lease obligations represent the present value of minimum lease payments under the respective agreement, payable monthly at various interest rates. Interest expense related to capital leases was less than $0.1 million for each of the three and nine months ended September 30, 2020, and was less than $0.1 million for each of the three and nine months ended September 30, 2019. As of September 30, 2020, future annual minimum payments required under lease obligations are as follows (in thousands): ​ ​ ​ ​ ​ Twelve months ending September 30, ​ ​ 2021 ​ $ 19,845 2022 ​ 1,241 Total ​ 21,086 Less amount representing interest ​ (218) ​ ​ 20,868 Current portion ​ (19,699) Long-term portion ​ $ 1,169 ​ At September 30, 2020 and December 31, 2019, equipment under capital leases consisted of patient equipment with a cost basis of $38.6 million and $39.1 million, respectively, and accumulated depreciation of approximately $11.6 million and $11.7 million, respectively. Depreciation expense for equipment purchased under capital leases is primarily included in cost of net revenue in the accompanying consolidated statements of operations. ​ Operating Leases ​ The Company leases its office facilities and office equipment under noncancelable lease agreements which expire at various dates through March 2033. Some of these lease agreements include an option to renew at the end of the term. The Company also leases certain patient medical equipment with such leases set to expire at various dates through November 2021. The Company also leases certain office facilities on a month to month basis. In some instances, the Company is also required to pay its pro rata share of real estate taxes and utility costs in connection with the premises. Some of the leases contain fixed annual increases of minimum rent. Accordingly, the Company recognizes rent expense on a straight-line basis and records the difference between the recognized rent expense and the amount payable under the lease as deferred rent. The deferred rent recorded in accounts payable and accrued expenses on the accompanying consolidated balance sheets at September 30, 2020 and December 31, 2019 was $1.3 million and $1.1 million, respectively. The Company recorded rent expense of $4.6 million and $2.9 million for the three months ended September 30, 2020 and 2019, respectively, and $11.9 million and $7.6 million for the nine months ended September 30, 2020 and 2019, respectively. These amounts are primarily included in cost of net revenue in the accompanying consolidated statements of operations. The minimum annual lease commitments under noncancelable leases with initial or remaining terms in excess of one year as of September 30, 2020 are as follows (in thousands): ​ ​ ​ ​ ​ Twelve months ending September 30, ​ ​ 2021 ​ $ 17,914 2022 ​ 13,945 2023 ​ 11,515 2024 ​ 9,187 2025 ​ 6,181 Thereafter ​ 16,854 Total minimum payments required (a) ​ $ 75,596 (a) Minimum payments have not been reduced by minimum sublease rentals of $2.1 million due in the future under noncancelable subleases.

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2020
Income Taxes
Income Taxes	(13) Income Taxes The Company is subject to U.S. federal, state, and local income taxes with respect to its allocable share of any taxable income or loss of AdaptHealth Holdings. AdaptHealth Holdings is treated as a partnership for U.S. income tax purposes and generally does not pay income taxes in most jurisdictions. Instead, AdaptHealth Holdings’ taxable income or loss is passed through to its members, including the Company. Additionally, the Company is subject to U.S. federal, state, and local income taxes on the taxable income or loss of the underlying C-corporations in the AdaptHealth group where taxes are paid at the entity level. For the three months ended September 30, 2020 and 2019, the Company recorded an income tax benefit of $0.6 million and income tax expense $1.0 million, respectively. For the nine months ended September 30, 2020 and 2019, the Company recorded income tax expense of $2.3 million and $5.4 million, respectively. As of September 30, 2020 and December 31, 2019, the Company had no uncertain tax positions that would require recognition or disclosure in the consolidated interim financial statements. Tax Receivable Agreement ​ AdaptHealth Corp. is party to a Tax Receivable Agreement (TRA) with certain current and former members of AdaptHealth Holdings. The TRA provides for the payment by AdaptHealth Corp. of 85% of the tax savings, if any, that AdaptHealth Corp. realizes (or is deemed to realize in certain circumstances) as a result of (i) certain increases in tax basis resulting from exchanges of New AdaptHealth Units and shares of Class B Common Stock; (ii) certain tax attributes of the corresponding sellers existing prior to an exchange; (iii) imputed interest deemed to be paid by AdapthHealth Corp. as a result of payments it makes under the TRA; and (iv) certain increases in tax basis resulting from payments AdaptHealth Corp. makes under the TRA. ​ During the nine months ended September 30, 2020, the Company increased its TRA liability through an aggregate $26.7 million reduction in additional-paid-in capital resulting from additional exchanges of New AdaptHealth Units and shares of Class B Common Stock. Correspondingly, during the nine months ended September 30, 2020, the Company increased its deferred tax asset by $23.0 million through an increase in additional-paid-in-capital resulting from these exchanges and other increases of AdaptHealth Corp.’s ownership interest in AdaptHealth Holdings. ​ At September 30, 2020 and December 31, 2019, the Company had a liability recorded relating to the TRA of approximately $38.1 million and $10.8 million, respectively, which is included in other long-term liabilities in the accompanying consolidated balance sheets.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2020
Commitments and Contingencies.
Commitments and Contingencies	(14) Commitments and Contingencies In the normal course of business, the Company is subject to loss contingencies, such as legal proceedings and claims arising out of its business that cover a wide range of matters. The Company records accruals for such loss contingencies when it is probable that a liability has been incurred and the amount of loss can be reasonably estimated. Significant judgement is required to determine both probability and the estimated amount. The Company reviews at least quarterly and adjusts accordingly to reflect the impact of negotiations, settlements, rulings, advice of legal counsel, and updated information. At this time, the Company has no accrual related to lawsuits, claims, investigations and proceedings. ​ In connection with the Company’s acquisition of PPS HME Holdings LLC (PPS) in May 2018, the Company assumed a Corporate Integrity Agreement (CIA) at one of PPS’ subsidiaries, Braden Partners L.P. d/b/a Pacific Pulmonary Services (BP). The CIA was entered into with the Office of Inspector General of the U.S. Department of Health and Human Services (OIG). The CIA has a five -year term which expires in April 2022. In connection with the acquisition and integration of PPS by AdaptHealth, the OIG confirmed that the requirements of the CIA imposed upon BP would only apply to the operations of BP and therefore no operations of any other AdaptHealth affiliate are subject to the requirements of the CIA following the acquisition. ​

Related Party Transactions

Related Party Transactions	9 Months Ended
	Sep. 30, 2020
Related Party Transactions
Related Party Transactions	(15) Related Party Transactions The Company has an outstanding note payable with a principal balance of $143.5 million with an investor who also has equity ownership in the Company. The Company and two of its executive officers and shareholders own an equity interest in a vendor of the Company that provides automated order intake software. Each individual’s equity ownership is less than 1%. The expense related to this vendor was $0.6 million and $0.6 million for the three months ended September 30, 2020 and 2019, respectively, and was $1.7 million and $1.5 million for the nine months ended September 30, 2020 and 2019, respectively. The Company accounts for this investment under the cost method of accounting based on its level of equity ownership. ​

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2020
Subsequent Events
Subsequent Events	(16) Subsequent Events On October 1, 2020, the Company acquired 100% of the equity interests of Pinnacle Medical Solutions, Inc. (Pinnacle). Pinnacle is primarily engaged in the business of distributing insulin pumps, insulin pump supplies, continuous glucose monitoring systems and diabetes test strips in the United States. The total consideration consisted of (i) a cash payment of $81.5 million at closing, (ii) the issuance of 1.0 million shares of the Company’s Class A Common Stock at closing, (iii) the potential issuance of up to 0.2 million shares of the Company’s Class A Common Stock in the future which were held back and subject to potential indemnification matters, and (iv) a potential contingent earnout payment of up to $15.0 million based on certain conditions after closing. The cash paid at closing included $2.6 million withheld in escrow to fund certain potential indemnification matters. As of the date the consolidated interim financial statements were available to be issued, the Company was in the process of determining the allocation of the fair value of the consideration paid to the fair value of the net assets acquired. ​

General Information (Policies)

General Information (Policies)	9 Months Ended
	Sep. 30, 2020
Summary of Significant Accounting Policies
Basis of Presentation	(a) Basis of Presentation The consolidated interim financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP). In the opinion of management, the consolidated interim financial statements include all necessary adjustments for a fair presentation of the financial position and results of operations for the periods presented. The Business Combination was accounted for as a reverse recapitalization, with DFB treated as the acquired company and AdaptHealth Holdings as the acquirer, for financial reporting purposes. Therefore, the equity structure has been restated to that of the Company. The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act of 1933, as amended, (the Securities Act), as modified by the Jumpstart our Business Startups Act of 2012, (the JOBS Act), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and other exemptions.
Basis of Consolidation	(b) Basis of Consolidation The accompanying consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.
Concentration of Credit Risk	(c) Concentration of Credit Risk Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash and trade accounts receivable. The Company maintains its cash in bank deposit accounts, which, at times, may exceed federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk on cash and cash equivalents.
Accounting Estimates	(d) Accounting Estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and reported amounts of revenues and expenses during the reporting period. Management bases these estimates and assumptions upon historical experience, existing and known circumstances, authoritative accounting pronouncements and other factors that management believes to be reasonable. Significant areas requiring the use of management estimates relate to revenue recognition and the valuation of accounts receivable (implicit price concession), income taxes, contingent consideration, equity-based compensation, interest rate swaps, and long-lived assets, including goodwill. Actual results could differ from those estimates.
Valuation of Goodwill and Intangible Assets	(e) Valuation of Goodwill and Intangible Assets The Company has a significant amount of goodwill on its balance sheet that resulted from the business acquisitions the Company has made in recent years. Goodwill is not amortized and is tested for impairment annually and upon the occurrence of a triggering event or change in circumstances indicating a possible impairment. Such changes in circumstance can include, among others, changes in the legal environment, reimbursement environment, operating performance, and/or future prospects. The Company performs its annual impairment review of goodwill during the fourth quarter of each year. The impairment testing can be performed on either a quantitative or qualitative basis. The Company first assesses qualitative factors to determine whether it is necessary to perform quantitative goodwill impairment testing. If determined necessary, the Company applies the quantitative impairment test to identify and measure the amount of impairment, if any. Definite-lived intangible assets consist of payor contracts, developed technology and tradenames. These assets are amortized using the straight-line method over their estimated useful lives, which reflects the pattern in which the economic benefits of the assets are expected to be consumed. These assets are tested for impairment consistent with the Company’s long-lived assets. The following table summarizes the useful lives of the intangible assets acquired: ​ ​ ​ ​ ​ Payor contracts 10 ​ years Developed technology 5 ​ years Tradenames 5 10 ​ years ​
Business segment	(f) Business Segment The Company’s chief operating decision-makers are its Chief Executive Officer and President, who make resource allocation decisions and assess performance based on financial information presented on an aggregate basis. There are no segment managers who are held accountable by the chief operating decision-makers, or anyone else, for any planning, strategy and key decision-making regarding operations. The corporate office is responsible for contract negotiation with vendors and payors, corporate compliance with healthcare laws and regulations, and revenue cycle management. Accordingly, the Company has a single reportable segment and operating segment structure.
Recent Accounting Pronouncements	(g) Recently Issued Accounting Pronouncements In February 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2016-02, Leases (Topic 842) (ASU 2016-02), which amended authoritative guidance on accounting for leases. The new provisions require that a lessee of operating leases recognize a liability to make lease payments and a right-of-use asset representing its right to use the underlying asset for the lease term. The Company is required to adopt the new standard for the annual reporting period beginning January 1, 2022, and interim reporting periods beginning January 1, 2023. The adoption of this standard is expected to have a material impact on the Company’s financial position. The Company is still evaluating the impact on its results of operations and does not expect the adoption of this standard to have an impact on liquidity. In January 2017, the FASB issued ASU 2017-04, Intangibles - Goodwill and Other (ASC Topic 350): Simplifying the Test for Goodwill Impairment ​ In December 2019, the FASB issued ASU 2019-12, “ Simplifying the Accounting for Income Taxes ​ In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments ​ In March 2020, the FASB issued ASU No. 2020-04, Reference Rate Reform (Topic 848)

General Information (Tables)

General Information (Tables)	9 Months Ended
	Sep. 30, 2020
General Information
Schedule of useful lives of acquired intangible assets	​ ​ ​ ​ ​ Payor contracts 10 ​ years Developed technology 5 ​ years Tradenames 5 10 ​ years

Revenue Recognition and Accou_2

Revenue Recognition and Accounts Receivable (Tables)	9 Months Ended
	Sep. 30, 2020
Revenue from Contract with Customer [Abstract]
Schedule of composition of net revenues by payor type and core service lines	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended September 30, ​ Nine Months Ended September 30, ​ ​ 2020 ​ 2019 2020 ​ 2019 Insurance ​ $ 175,418 ​ $ 77,136 ​ $ 438,034 ​ $ 213,762 Government ​ ​ 81,967 ​ ​ 43,679 ​ ​ 193,725 ​ ​ 122,358 Patient pay ​ 27,020 ​ 15,636 ​ 76,201 ​ 43,983 Net revenue ​ $ 284,405 ​ $ 136,451 ​ $ 707,960 ​ $ 380,103 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended September 30, ​ Nine Months Ended September 30, ​ ​ 2020 ​ 2019 2020 ​ 2019 Net sales revenue: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Sleep ​ $ 74,655 ​ $ 59,117 ​ $ 227,970 ​ $ 156,677 Diabetes ​ ​ 52,887 ​ ​ — ​ ​ 64,566 ​ ​ — Supplies to the home ​ ​ 44,579 ​ ​ 1,966 ​ ​ 100,479 ​ ​ 5,910 Respiratory ​ 5,152 ​ 1,397 ​ 26,034 ​ 4,121 HME ​ ​ 14,998 ​ ​ 10,873 ​ ​ 39,304 ​ ​ 31,598 Other ​ ​ 14,869 ​ ​ 9,711 ​ ​ 38,725 ​ ​ 26,710 Total net sales revenue ​ $ 207,140 ​ $ 83,064 ​ $ 497,078 ​ $ 225,016 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net revenue from fixed monthly equipment reimbursements: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Sleep ​ $ 24,971 ​ $ 20,761 ​ $ 70,284 ​ $ 57,762 Diabetes ​ ​ 946 ​ ​ — ​ ​ 946 ​ ​ — Respiratory ​ 32,269 ​ 19,646 ​ 88,132 ​ 60,084 HME ​ ​ 14,256 ​ ​ 11,088 ​ ​ 39,695 ​ ​ 31,533 Other ​ ​ 4,823 ​ ​ 1,892 ​ ​ 11,825 ​ ​ 5,708 Total net revenue from fixed monthly equipment reimbursements ​ $ 77,265 ​ $ 53,387 ​ $ 210,882 ​ $ 155,087 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total net revenue: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Sleep ​ $ 99,626 ​ $ 79,878 ​ $ 298,254 ​ $ 214,439 Diabetes ​ ​ 53,833 ​ ​ — ​ ​ 65,512 ​ ​ — Supplies to the home ​ ​ 44,579 ​ ​ 1,966 ​ ​ 100,479 ​ ​ 5,910 Respiratory ​ 37,421 ​ 21,043 ​ 114,166 ​ 64,205 HME ​ ​ 29,254 ​ ​ 21,961 ​ ​ 78,999 ​ ​ 63,131 Other ​ ​ 19,692 ​ ​ 11,603 ​ ​ 50,550 ​ ​ 32,418 Total net revenue ​ $ 284,405 ​ $ 136,451 ​ $ 707,960 ​ $ 380,103

Significant Transactions (Table

Significant Transactions (Tables)	9 Months Ended
	Sep. 30, 2020
Business Acquisition
Schedule of proforma net revenue and operating income	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ (in thousands) ​ Three Months Ended September 30, ​ Nine Months Ended September 30, ​ ​ ​ 2020 2019 2020 2019 ​ Net revenue ​ $ 284,405 ​ $ 255,731 ​ $ 835,177 ​ $ 732,999 ​ Operating income ​ $ 13,259 ​ $ 12,785 ​ $ 53,600 ​ $ 33,921 ​
Summary of results of business acquired	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ (in thousands) ​ Three Months Ended September 30, ​ Nine Months Ended September 30, ​ ​ ​ 2020 2019 2020 2019 ​ Net revenue ​ $ 115,077 ​ $ 16,137 ​ $ 208,803 ​ $ 33,732 ​ Operating income (loss) ​ $ 4,637 ​ $ 1,872 ​ $ (2,984) ​ $ 5,285 ​
Significant Acquisitions In 2020 [Member]
Business Acquisition
Summary of consideration	​ ​ ​ ​ ​ Cash consideration ​ $ 623,107 Equity consideration ​ 89,529 Contingent consideration ​ ​ 6,464 Deferred payments ​ 33 Total ​ $ 719,133
Summary of estimated fair values of the net assets acquired	​ ​ ​ ​ ​ Cash ​ $ 17,798 Accounts receivable ​ 49,464 Inventory ​ 23,073 Prepaid and other current assets ​ 4,254 Equipment and other fixed assets ​ 42,852 Goodwill ​ 543,689 Intangible assets ​ ​ 97,400 Accounts payable and accrued expenses ​ (47,759) Contract liabilities ​ ​ (3,675) Other current liabilities ​ ​ (5,069) Other long-term liabilities ​ ​ (1,186) Capital lease obligations ​ (1,708) Net assets acquired ​ $ 719,133
Significant acquisitions in 2019
Business Acquisition
Summary of consideration	​ ​ ​ ​ Cash consideration $ 47,763 Seller note 2,000 Contingent consideration 6,425 Deferred payments ​ 1,500 Total $ 57,688
Summary of estimated fair values of the net assets acquired	​ ​ ​ ​ ​ ​ Total Cash $ 117 Accounts receivable 3,404 Inventory 4,173 Prepaid and other current assets 12 Equipment and other fixed assets 10,238 Goodwill 43,883 Contract liabilities ​ (1,512) Accounts payable and accrued expenses (2,627) Net assets acquired $ 57,688

Equipment and Other Fixed Ass_2

Equipment and Other Fixed Assets (Tables)	9 Months Ended
	Sep. 30, 2020
Equipment and Other Fixed Assets
Schedule of equipment and other fixed assets	​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, ​ December 31, ​ ​ 2020 2019 Patient medical equipment ​ $ 151,634 $ 112,071 Delivery vehicles ​ 7,150 4,461 Other ​ 25,023 15,474 ​ ​ 183,807 ​ 132,006 Less accumulated depreciation ​ (82,151) ​ (68,447) ​ ​ $ 101,656 ​ $ 63,559

Goodwill and Identifiable Int_2

Goodwill and Identifiable Intangible Assets (Tables)	9 Months Ended
	Sep. 30, 2020
Goodwill.
Schedule of change in the carrying amount of goodwill	​ ​ ​ ​ ​ Balance at December 31, 2019 ​ $ 266,791 Acquired goodwill during the period ​ ​ 543,689 Balance at September 30, 2020 ​ $ 810,480
Schedule of identifiable intangible assets	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted-Average ​ ​ ​ ​ ​ Remaining Life (Years) Payor contracts, net of accumulated amortization of $1,500 ​ $ 58,500 ​ 9.8 Developed technology, net of accumulated amortization of $345 ​ ​ 6,655 ​ 4.8 Tradenames, net of accumulated amortization of $830 ​ ​ 29,570 ​ 9.5 Identifiable intangible assets, net ​ $ 94,725 ​ ​
Schedule of future amortization expense related to identifiable intangible assets	​ ​ ​ ​ ​ Twelve months ending September 30, ​ ​ 2021 ​ $ 10,650 2022 ​ 10,596 2023 ​ 10,596 2024 ​ 10,596 2025 ​ 10,124 Thereafter ​ 42,163 Total ​ $ 94,725

Fair Value of Assets and Liab_2

Fair Value of Assets and Liabilities (Tables)	9 Months Ended
	Sep. 30, 2020
Fair Value of Assets and Liabilities
Summary of financial assets and liabilities measured at fair value on a recurring basis	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ (in thousands) Level 1 Level 2 Level 3 Fair Value September 30, 2020 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Assets ​ ​ ​ ​ Money market accounts ​ $ 198,919 ​ $ — ​ $ — ​ $ 198,919 Total assets measured at fair value ​ $ 198,919 ​ $ — ​ $ — ​ $ 198,919 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Liabilities ​ ​ ​ ​ Acquisition-related contingent consideration-short term ​ $ — ​ $ — ​ $ 3,789 ​ $ 3,789 Acquisition-related contingent consideration-long term ​ — ​ — ​ 13,346 ​ 13,346 Interest rate swap agreements-short term ​ ​ — ​ ​ 5,890 ​ ​ — ​ ​ 5,890 Interest rate swap agreements-long term ​ — ​ 11,877 ​ — ​ 11,877 Total liabilities measured at fair value ​ $ — ​ $ 17,767 ​ $ 17,135 ​ $ 34,902 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ (in thousands) Level 1 Level 2 Level 3 Fair Value December 31, 2019 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Assets ​ ​ ​ ​ Money market accounts ​ $ 54,015 ​ $ — ​ $ — ​ $ 54,015 Total assets measured at fair value ​ $ 54,015 ​ $ — ​ $ — ​ $ 54,015 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Liabilities ​ ​ ​ ​ Acquisition-related contingent consideration-short term ​ $ — ​ $ — ​ $ 4,825 ​ $ 4,825 Acquisition-related contingent consideration-long term ​ — ​ — ​ 9,900 ​ 9,900 Interest rate swap agreements-short term ​ ​ — ​ ​ 2,157 ​ ​ — ​ ​ 2,157 Interest rate swap agreements-long term ​ — ​ 6,182 ​ — ​ 6,182 Total liabilities measured at fair value ​ $ — ​ $ 8,339 ​ $ 14,725 ​ $ 23,064
Reconciliation of contingent consideration liabilities related to acquisitions	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Nine Months Ended September 30, 2020 ​ Beginning Balance Additions Payments Change in Fair Value Other activity Ending Balance Contingent consideration - Level 3 liabilities ​ $ 14,725 ​ $ 6,464 ​ $ (1,200) ​ $ (2,900) ​ $ 46 ​ $ 17,135 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Nine Months Ended September 30, 2019 ​ Beginning Balance Additions Payments Change in Fair Value Other activity Ending Balance Contingent consideration - Level 3 liabilities ​ $ 15,250 ​ $ 6,425 ​ $ (13,000) ​ $ (625) $ — ​ $ 8,050
Summary of non-financial assets measured on a non-recurring basis	​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, ​ December 31, ​ ​ 2020 2019 Assets: ​ ​ ​ Goodwill (Level 3) ​ $ 810,480 ​ $ 266,791 Identifiable intangible assets, net (Level 3) ​ ​ 94,725 ​ ​ —

Derivative Instruments and He_2

Derivative Instruments and Hedging Activities (Tables)	9 Months Ended
	Sep. 30, 2020
Derivative Instruments and Hedging Activities
Summary of fair value of derivative financial instruments as well as their classification on the consolidated balance sheets	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, 2020 ​ December 31, 2019 ​ ​ Balance Sheet Location ​ Asset (Liability) Interest rate swap agreements ​ Other current liabilities ​ $ (5,890) ​ $ (2,157) Interest rate swap agreements ​ Other long-term liabilities ​ (11,877) ​ (6,182) Total ​ ​ ​ $ (17,767) ​ $ (8,339) ​

Accounts Payable and Accrued _2

Accounts Payable and Accrued Expenses (Tables)	9 Months Ended
	Sep. 30, 2020
Accounts Payable and Accrued Expenses
Schedule of components accounts payable and accrued expenses	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, ​ December 31, ​ ​ 2020 ​ 2019 Accounts payable ​ $ 144,804 $ 79,237 Employee related accruals ​ 17,550 ​ 12,320 Accrued interest ​ 10,294 ​ 4,022 Other ​ 19,689 ​ 7,149 Total ​ $ 192,337 ​ $ 102,728

Debt (Tables)

Debt (Tables)	9 Months Ended
	Sep. 30, 2020
Debt
Schedule of summary of long term debt	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, ​ December 31, ​ ​ 2020 ​ 2019 Secured term loans ​ $ 250,000 $ 246,250 Revolving credit facility ​ ​ — ​ ​ 12,000 Senior unsecured notes ​ ​ 350,000 ​ ​ — Note payable ​ 143,500 ​ 143,500 Other ​ 666 ​ 1,725 Unamortized discount on senior unsecured notes ​ ​ (5,997) ​ ​ — Unamortized deferred financing fees ​ (6,960) ​ (6,642) ​ ​ 731,209 ​ 396,833 Current portion ​ (8,479) ​ (1,721) Long-term portion ​ $ 722,730 ​ $ 395,112

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	9 Months Ended
	Sep. 30, 2020
Business Acquisition
Nonvested Restricted Stock Shares Activity [Table Text Block]	​ ​ ​ ​ ​ ​ ​ ​ ​ Number of Shares of ​ ​ Weighted-Average Grant Date ​ ​ Restricted Stock ​ Fair Value per Share Non-vested balance at January 1, 2020 ​ 901 $ 5.83 Granted ​ 2,050 ​ $ 18.32 Vested ​ (44) ​ $ 12.04 Forfeited ​ (39) ​ $ 10.85 Non-vested balance at September 30, 2020 ​ 2,868 ​ $ 14.54
Options
Business Acquisition
Schedule of assumptions used to determine the grant date fair value	​ ​ ​ ​ ​ ​ ​ ​ ​ Expected volatility 40.7 % Risk-free interest rate 0.4 % Expected term 6.0 years Dividend yield ​ N/A ​

Earnings Per Share (Tables)

Earnings Per Share (Tables)	9 Months Ended
	Sep. 30, 2020
Earnings per share
Schedule of calculation of basic and diluted earnings per share	​

Leases (Tables)

Leases (Tables)	9 Months Ended
	Sep. 30, 2020
Lease Commitments
Summary of future annual minimum payments required under lease obligations	​ ​ ​ ​ ​ Twelve months ending September 30, ​ ​ 2021 ​ $ 19,845 2022 ​ 1,241 Total ​ 21,086 Less amount representing interest ​ (218) ​ ​ 20,868 Current portion ​ (19,699) Long-term portion ​ $ 1,169
Summary of minimum annual lease commitments under noncancelable leases	​ ​ ​ ​ ​ Twelve months ending September 30, ​ ​ 2021 ​ $ 17,914 2022 ​ 13,945 2023 ​ 11,515 2024 ​ 9,187 2025 ​ 6,181 Thereafter ​ 16,854 Total minimum payments required (a) ​ $ 75,596 (a) Minimum payments have not been reduced by minimum sublease rentals of $2.1 million due in the future under noncancelable subleases.

General Information (Details)

General Information (Details)	9 Months Ended
	Sep. 30, 2020
Payor contracts
Property, Plant and Equipment [Line Items]
Finite-Lived Intangible Asset, Useful Life	10 years
Developed technology
Property, Plant and Equipment [Line Items]
Finite-Lived Intangible Asset, Useful Life	5 years
Minimum | Tradenames [Member]
Property, Plant and Equipment [Line Items]
Finite-Lived Intangible Asset, Useful Life	5 years
Maximum | Tradenames [Member]
Property, Plant and Equipment [Line Items]
Finite-Lived Intangible Asset, Useful Life	10 years

Revenue Recognition and Accou_3

Revenue Recognition and Accounts Receivable (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended		9 Months Ended
	Apr. 30, 2020	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Revenue Recognition
Total net revenues		$ 284,405	$ 136,451	$ 707,960	$ 380,103
Recoupable Advance Payment, CARES Act	$ 45,800
Receipt of provider relief funds, CARES Act	$ 17,200
Total funds, CARES Act		63,000		63,000
Unbilled revenue		18,500		18,500		$ 8,600
Transferred at Point in Time [Member]
Revenue Recognition
Total net revenues		207,140	83,064	497,078	225,016
Transferred over Time [Member]
Revenue Recognition
Total net revenues		77,265	53,387	210,882	155,087
Sleep
Revenue Recognition
Total net revenues		99,626	79,878	298,254	214,439
Sleep | Transferred at Point in Time [Member]
Revenue Recognition
Total net revenues		74,655	59,117	227,970	156,677
Sleep | Transferred over Time [Member]
Revenue Recognition
Total net revenues		24,971	20,761	70,284	57,762
Diabetes [Member]
Revenue Recognition
Total net revenues		53,833		65,512
Diabetes [Member] | Transferred at Point in Time [Member]
Revenue Recognition
Total net revenues		52,887		64,566
Diabetes [Member] | Transferred over Time [Member]
Revenue Recognition
Total net revenues		946		946
Supplies to the home
Revenue Recognition
Total net revenues		44,579	1,966	100,479	5,910
Supplies to the home | Transferred at Point in Time [Member]
Revenue Recognition
Total net revenues		44,579	1,966	100,479	5,910
HME
Revenue Recognition
Total net revenues		29,254	21,961	78,999	63,131
HME | Transferred at Point in Time [Member]
Revenue Recognition
Total net revenues		14,998	10,873	39,304	31,598
HME | Transferred over Time [Member]
Revenue Recognition
Total net revenues		14,256	11,088	39,695	31,533
Respiratory
Revenue Recognition
Total net revenues		37,421	21,043	114,166	64,205
Respiratory | Transferred at Point in Time [Member]
Revenue Recognition
Total net revenues		5,152	1,397	26,034	4,121
Respiratory | Transferred over Time [Member]
Revenue Recognition
Total net revenues		32,269	19,646	88,132	60,084
Other
Revenue Recognition
Total net revenues		19,692	11,603	50,550	32,418
Other | Transferred at Point in Time [Member]
Revenue Recognition
Total net revenues		14,869	9,711	38,725	26,710
Other | Transferred over Time [Member]
Revenue Recognition
Total net revenues		4,823	1,892	11,825	5,708
Insurance Payor [Member]
Revenue Recognition
Total net revenues		175,418	77,136	438,034	213,762
Government payor
Revenue Recognition
Total net revenues		81,967	43,679	193,725	122,358
Patient payor
Revenue Recognition
Total net revenues		$ 27,020	$ 15,636	$ 76,201	$ 43,983

Significant Transactions - Cons

Significant Transactions - Consideration and Allocation (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Jul. 01, 2020	Mar. 02, 2020	Jan. 02, 2020	Dec. 31, 2019	Jul. 05, 2019	Jan. 02, 2019
Estimated fair values of net assets acquired
Cash		$ 117
Accounts receivable		3,404
Inventory		4,173
Prepaid and other current assets		12
Equipment and other fixed assets		10,238
Goodwill	$ 810,480	43,883				$ 266,791
Accounts payable and accrued expenses		(2,627)
Contract liabilities		(1,512)
Net assets acquired		57,688
Business Combination, Consideration Transferred, Including Equity Interest in Acquiree Held Prior to Combination [Abstract]
Equity consideration issued in connection with acquisitions	89,529
Liability incurred		2,000
Deferred payments	6,464	6,425
Payment of working capital adjustment from 2018 acquisitions		300
Significant Acquisitions In 2020 [Member]
Estimated fair values of net assets acquired
Cash	17,798
Accounts receivable	49,464
Inventory	23,073
Prepaid and other current assets	4,254
Equipment and other fixed assets	42,852
Intangible assets	97,400
Goodwill	543,689
Accounts payable and accrued expenses	(47,759)
Contract liabilities	(3,675)
Net liabilities - working capital	(5,069)
Other long-term liabilities	(1,186)
Capital lease obligations	(1,708)
Net assets acquired	719,133
Business Combination, Consideration Transferred, Including Equity Interest in Acquiree Held Prior to Combination [Abstract]
Cash payment	623,107
Equity consideration issued in connection with acquisitions	89,529
Contingent consideration	6,464
Deferred payments	33
Total consideration	$ 719,133
Patient Care Solutions (PCS) [Member]
Business Acquisition
Interest acquired, as a percent					100.00%
Estimated fair values of net assets acquired
Accounts receivable					$ 17,400
Equipment and other fixed assets					500
Goodwill					100
Net liabilities - working capital					$ (4,000)
Advanced Home Care Inc [Member]
Estimated fair values of net assets acquired
Inventory				$ 2,700
Equipment and other fixed assets				21,000
Intangible assets				600
Goodwill				35,800
Net liabilities - working capital				(1,600)
Potential contingent payment				$ 9,000
Solara Medical Supplies, LLC [Member]
Business Acquisition
Interest acquired, as a percent			100.00%
Estimated fair values of net assets acquired
Cash			$ 12,100
Accounts receivable			15,100
Inventory			15,000
Equipment and other fixed assets			4,400
Intangible assets			85,700
Goodwill			347,100
Accounts payable and accrued expenses			(22,400)
Net liabilities - working capital			$ (3,000)
ActivStyle, Inc. [Member]
Business Acquisition
Interest acquired, as a percent			100.00%
Estimated fair values of net assets acquired
Cash			$ 5,000
Accounts receivable			4,100
Inventory			500
Net assets - working capital			900
Equipment and other fixed assets			1,000
Intangible assets			10,100
Goodwill			51,200
Accounts payable and accrued expenses			$ (7,300)
Significant acquisitions in 2019
Business Combination, Consideration Transferred, Including Equity Interest in Acquiree Held Prior to Combination [Abstract]
Cash payment		47,763
Liability incurred		2,000
Contingent consideration		6,425
Deferred payments		1,500
Total consideration		$ 57,688
Gould's
Business Acquisition
Interest acquired, as a percent								100.00%
Estimated fair values of net assets acquired
Accounts receivable								$ 3,700
Inventory								2,400
Equipment and other fixed assets								1,700
Goodwill								19,100
Net liabilities - working capital								(2,600)
Potential contingent payment								$ 1,500
SleepMed
Estimated fair values of net assets acquired
Inventory							$ 300
Equipment and other fixed assets							1,300
Goodwill							14,100
Net liabilities - working capital							(300)
Potential contingent payment							$ 4,000

Significant Transactions - Pro-

Significant Transactions - Pro-forma Financial Information and Results of Business Acquired (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Pro-forma financial information:
Pro-forma net revenue	$ 284,405	$ 255,731	$ 835,177	$ 732,999
Pro-forma operating income	13,259	12,785	53,600	33,921
Net revenue since acquisition date	115,077	16,137	208,803	33,732
Operating income (loss) since acquisition date	$ 4,637	$ 1,872	$ (2,984)	$ 5,285

Significant Transactions - Busi

Significant Transactions - Business Combination (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2020USD ($)item	Nov. 08, 2019
Business Acquisition, Equity Interests Issued or Issuable [Line Items]
Payments to acquire cost method investments | $	$ 1,000
Adapt Health Holdings LLC
Business Acquisition, Equity Interests Issued or Issuable [Line Items]
Controlling interest, as a percent		56.00%
Class A Common Stock | Shareholders of Adapt Health Holdings LLC | Adapt Health Holdings LLC
Business Acquisition, Equity Interests Issued or Issuable [Line Items]
Noncontrolling interest, as a percent	24.00%	44.00%
Class B Common Stock
Business Acquisition, Equity Interests Issued or Issuable [Line Items]
Number of votes per share | item	1

Equipment and Other Fixed Ass_3

Equipment and Other Fixed Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Property, Plant and Equipment [Line Items]
Equipment and other fixed assets, gross	$ 183,807	$ 132,006
Less accumulated depreciation	(82,151)	(68,447)
Equipment and other fixed assets, net	101,656	63,559
Patient medical equipment
Property, Plant and Equipment [Line Items]
Equipment and other fixed assets, gross	151,634	112,071
Delivery vehicles
Property, Plant and Equipment [Line Items]
Equipment and other fixed assets, gross	7,150	4,461
Other
Property, Plant and Equipment [Line Items]
Equipment and other fixed assets, gross	$ 25,023	$ 15,474

Goodwill and Identifiable Int_3

Goodwill and Identifiable Intangible Assets (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Net carrying amount
Beginning balance			$ 266,791,000
Acquired goodwill during the period			543,689,000
Ending balance	$ 810,480,000	$ 43,883,000	810,480,000	$ 43,883,000
Goodwill, Impairment Loss	$ 0	$ 0	$ 0	$ 0

Goodwill and Identifiable Int_4

Goodwill and Identifiable Intangible Assets - Intangible Assets (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Finite-Lived Intangible Assets [Line Items]
Amortization of intangible assets	$ 2,700	$ 0	$ 2,675	$ 0
Finite-Lived Intangible Assets, Net, Amortization Expense, Rolling Maturity [Abstract]
2021	10,650		10,650
2022	10,596		10,596
2023	10,596		10,596
2024	10,596		10,596
2025	10,124		10,124
Thereafter	42,163		42,163
Finite-Lived Intangible Assets, Net, Total	94,725		94,725		$ 0
Impairment of Intangible Assets, Finite-lived	0	$ 0	0	$ 0
Payor contracts
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Accumulated Amortization	1,500		$ 1,500
Finite-Lived Intangible Assets, Remaining Amortization Period			9 years 9 months 18 days
Finite-Lived Intangible Assets, Net, Amortization Expense, Rolling Maturity [Abstract]
Finite-Lived Intangible Assets, Net, Total	58,500		$ 58,500
Tradenames [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Accumulated Amortization	830		$ 830
Finite-Lived Intangible Assets, Remaining Amortization Period			9 years 6 months
Finite-Lived Intangible Assets, Net, Amortization Expense, Rolling Maturity [Abstract]
Finite-Lived Intangible Assets, Net, Total	29,570		$ 29,570
Developed technology
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Accumulated Amortization	345		$ 345
Finite-Lived Intangible Assets, Remaining Amortization Period			4 years 9 months 18 days
Finite-Lived Intangible Assets, Net, Amortization Expense, Rolling Maturity [Abstract]
Finite-Lived Intangible Assets, Net, Total	$ 6,655		$ 6,655

Fair Value of Assets and Liab_3

Fair Value of Assets and Liabilities - Valuation of Financial Assets and Liabilities (Details) - Recurring - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Assets
Total assets measured at fair value	$ 198,919	$ 54,015
Liabilities
Total liabilities measured at fair value	34,902	23,064
Acquisition-related contingent consideration obligations-short term
Liabilities
Total liabilities measured at fair value	3,789	4,825
Acquisition-related contingent consideration obligations-long term
Liabilities
Total liabilities measured at fair value	13,346	9,900
Interest Rate Swap Short-term [Member]
Liabilities
Total liabilities measured at fair value	5,890	2,157
Interest Rate Swap Long-term [Member]
Liabilities
Total liabilities measured at fair value	11,877	6,182
Money market accounts
Assets
Total assets measured at fair value	198,919	54,015
Level 1
Assets
Total assets measured at fair value	198,919	54,015
Level 1 | Money market accounts
Assets
Total assets measured at fair value	198,919	54,015
Level 2
Liabilities
Total liabilities measured at fair value	17,767	8,339
Level 2 | Interest Rate Swap Short-term [Member]
Liabilities
Total liabilities measured at fair value	5,890	2,157
Level 2 | Interest Rate Swap Long-term [Member]
Liabilities
Total liabilities measured at fair value	11,877	6,182
Level 3
Liabilities
Total liabilities measured at fair value	17,135	14,725
Level 3 | Acquisition-related contingent consideration obligations-short term
Liabilities
Total liabilities measured at fair value	3,789	4,825
Level 3 | Acquisition-related contingent consideration obligations-long term
Liabilities
Total liabilities measured at fair value	$ 13,346	$ 9,900

Fair Value - Contingent Conside

Fair Value - Contingent Consideration (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Business Acquisition, Contingent Consideration [Line Items]
Contingent consideration liability at beginning of period	$ 14,725	$ 15,250
Additions	6,464	6,425
Payments	(1,200)	(13,000)
Gain	(2,900)	(625)
Other activity	46
Contingent consideration liability at end of period	17,135	$ 8,050
Level 3 | Other current liabilities
Business Acquisition, Contingent Consideration [Line Items]
Contingent consideration liability at beginning of period	4,800
Contingent consideration liability at end of period	3,800
Level 3 | Other long-term liabilities
Business Acquisition, Contingent Consideration [Line Items]
Contingent consideration liability at beginning of period	9,900
Contingent consideration liability at end of period	$ 13,300

Fair Value of Assets and Liab_4

Fair Value of Assets and Liabilities - Non-financial Assets Measured on Non-recurring Basis (Details) - Nonrecurring - Level 3 - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Goodwill (annual impairment assessment)	$ 810,480	$ 266,791
Finite-lived Intangible Assets, Fair Value Disclosure	$ 94,725

Derivative Instruments and He_3

Derivative Instruments and Hedging Activities - Financial instruments (Details) - Derivatives designated as hedging instruments - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Derivative financial instruments
Fair Value Liability	$ (17,767)	$ (8,339)
Interest rate swap agreements
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Notional amount	250,000	250,000
Interest rate swap agreements | Other current liabilities
Derivative financial instruments
Fair Value Liability	(5,890)	(2,157)
Interest rate swap agreements | Other long-term liabilities
Derivative financial instruments
Fair Value Liability	$ (11,877)	$ (6,182)

Derivative Instruments and He_4

Derivative Instruments and Hedging Activities - Effect on Accumulated Other Comprehensive Income (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Derivative Instruments and Hedging Activities
Amount of Gain or (Loss) Recognized in OCI on Derivative	$ (1.6)	$ 1.1	$ (9.4)	$ 1.1
Amount of Gain or (Loss) Reclassified from Accumulated OCI into Income	$ 0.7	$ 0.2	$ 2.1	$ 0.2

Derivative Instruments and He_5

Derivative Instruments and Hedging Activities - Not designated (Details) - USD ($) $ in Millions	3 Months Ended	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2019
Interest rate swap agreements | Interest expense
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain or (Loss) Recognized in Income on Derivative	$ (2.9)	$ (12.4)

Accounts Payable and Accrued _3

Accounts Payable and Accrued Expenses (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Accounts Payable and Accrued Expenses
Accounts payable	$ 144,804	$ 79,237
Employee related accruals	17,550	12,320
Accrued interest	10,294	4,022
Other	19,689	7,149
Accounts payable and accrued expenses	$ 192,337	$ 102,728

Debt (Details)

Debt (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Jul. 31, 2020	Dec. 31, 2019	Mar. 31, 2019
Debt Instrument [Line Items]
Unamortized discount on senior unsecured notes	$ (5,997)
Unamortized deferred financing fees	(6,960)		$ (6,642)
Debt, Net	731,209		396,833
Current portion	(8,479)		(1,721)
Long-term portion	722,730		395,112
Revolving Credit Loans Maturing July 2025 [Member]
Debt Instrument [Line Items]
Borrowing capacity		$ 200,000
Revolver Letter Of Credit Sublimit Maturing July 2025. [Member]
Debt Instrument [Line Items]
Debt, Gross	4,000
Borrowing capacity		15,000
Term Loan Maturing July 2025 [Member]
Debt Instrument [Line Items]
Debt, Gross	250,000
Senior Notes 6.125 Percent Due 2028 [Member]
Debt Instrument [Line Items]
Debt, Gross	350,000
Unamortized discount on senior unsecured notes		(6,100)
Unamortized deferred financing fees		$ (2,300)
Credit Facility [Member]
Debt Instrument [Line Items]
Borrowing capacity				$ 425,000
Secured term loans
Debt Instrument [Line Items]
Debt, Gross			246,250
Initial/credit facility term loan
Debt Instrument [Line Items]
Debt, Gross	250,000
Borrowing capacity				300,000
Delayed Draw Term Loan
Debt Instrument [Line Items]
Borrowing capacity				50,000
Revolving credit facility/revolver
Debt Instrument [Line Items]
Debt, Gross			12,000
Borrowing capacity				$ 75,000
New Promissory Note
Debt Instrument [Line Items]
Debt, Gross	143,500		143,500
Other
Debt Instrument [Line Items]
Debt, Gross	$ 666		$ 1,725

Debt - Long term debt (Details)

Debt - Long term debt (Details) - USD ($) $ in Thousands	1 Months Ended		3 Months Ended		9 Months Ended
	Jul. 31, 2020	Mar. 31, 2019	Sep. 30, 2020	Mar. 31, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Debt Instrument [Line Items]
Payments of Debt Issuance Costs						$ 9,000
Write-off of deferred financing costs					$ 5,316	2,121
Proceeds from Lines of Credit	$ 216,300				536,275	345,500
Repayment of credit facility		$ 151,900
Distributions to members		250,000		$ 250,000
Redemption of members' interest		3,700		3,713
Repayment of loan					545,584	$ 156,062
Credit Agreement Maturing July 2025 [Member]
Debt Instrument [Line Items]
Payments of Debt Issuance Costs	2,700
Revolving Credit Loans Maturing July 2025 [Member]
Debt Instrument [Line Items]
Borrowing capacity	$ 200,000
Revolver balance			$ 0		0
Remaining maximum borrowings available			196,000		196,000
Revolving Credit Loans Maturing July 2025 [Member] | Minimum
Debt Instrument [Line Items]
Commitment fee (as a percent)	0.25%
Revolving Credit Loans Maturing July 2025 [Member] | Maximum
Debt Instrument [Line Items]
Commitment fee (as a percent)	0.50%
Revolver Letter Of Credit Sublimit Maturing July 2025. [Member]
Debt Instrument [Line Items]
Borrowing capacity	$ 15,000
Debt balance outstanding			4,000		4,000
Term Loan Maturing July 2025 [Member]
Debt Instrument [Line Items]
Face amount	$ 250,000
Debt balance outstanding			250,000		250,000
Term Loan Maturing July 2025 [Member] | Minimum
Debt Instrument [Line Items]
Rate margin (as a percent)	2.50%
Term Loan Maturing July 2025 [Member] | Maximum
Debt Instrument [Line Items]
Rate margin (as a percent)	3.75%
Credit Facility [Member]
Debt Instrument [Line Items]
Borrowing capacity		425,000		425,000
Write-off of deferred financing costs			5,300		5,300
Repayment of credit facility	$ 523,900
Secured term loans
Debt Instrument [Line Items]
Debt balance outstanding							$ 246,250
Initial/credit facility term loan
Debt Instrument [Line Items]
Borrowing capacity		300,000		300,000
Quarterly principal repayments					1,600
Debt balance outstanding			$ 250,000		$ 250,000
Credit facility Interest rate			3.69%		3.69%
Delayed Draw Term Loan
Debt Instrument [Line Items]
Borrowing capacity		50,000		50,000
Quarterly principal repayments					$ 3,100
Revolving credit facility/revolver
Debt Instrument [Line Items]
Borrowing capacity		$ 75,000		$ 75,000
Payments of Debt Issuance Costs	$ 1,800
Debt balance outstanding							$ 12,000

Debt - Notes (Details)

Debt - Notes (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended				3 Months Ended	9 Months Ended
	Sep. 30, 2020	Jul. 31, 2020	May 31, 2020	Mar. 31, 2019	Sep. 30, 2020	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Debt Instrument [Line Items]
Proceeds from the issuance of senior unsecured notes, net of related discount						$ 343,875
Debt Instrument, Unamortized Discount	$ 5,997				$ 5,997	5,997
Debt Issuance Costs, Net	6,960				6,960	6,960		$ 6,642
Proceeds from issuance of members' interests				$ 20,000			$ 20,000
Current tax liability associated with recapitalization	0				0	$ 0		$ 5,900
Number of shares in Consideration Unit			1
Number of shares under Put/Call Option and Consent Agreement			1,898,967
Minimum fixed purchase price (in dollars per share)			$ 14.50
Minimum variable price, as percent of weighted average price			85.00%
Sales price (in dollars per share)			$ 15.76
Accumulated Deficit
Debt Instrument [Line Items]
Equity activity resulting from the Put/Call Agreement	2,700				2,694
Additional paid-in capital
Debt Instrument [Line Items]
Equity activity resulting from the Put/Call Agreement	$ (2,700)				$ (2,694)
New Promissory Note | Period starting on the closing date and ending on the seventh anniversary
Debt Instrument [Line Items]
Debt Interest rate	12.00%				12.00%	12.00%
New Promissory Note | Period starting on the day after the seventh anniversary of the closing date and ending on the maturity date
Debt Instrument [Line Items]
Interest rate payable in cash						6.00%
Interest rate payable in kind						6.00%
New Promissory Note | Make-whole Premium, First Period [Member]
Debt Instrument [Line Items]
Make-whole premium, as a percent						15.00%
New Promissory Note | Make-whole Premium, Second Period [Member]
Debt Instrument [Line Items]
Make-whole premium, as a percent						10.00%
New Promissory Note | Make-whole Premium, Third Period [Member]
Debt Instrument [Line Items]
Make-whole premium, as a percent						5.00%
New Promissory Note | Minimum | Period starting on the day after the seventh anniversary of the closing date and ending on the maturity date
Debt Instrument [Line Items]
Debt Interest rate	15.00%				15.00%	15.00%
New Promissory Note | Twelve-month LIBOR | Minimum | Period starting on the day after the seventh anniversary of the closing date and ending on the maturity date
Debt Instrument [Line Items]
Rate margin (as a percent)						12.00%
Promissory Note With Investor [Member]
Debt Instrument [Line Items]
Face amount				100,000
Promissory Note From Members Interest [Member]
Debt Instrument [Line Items]
Face amount				$ 43,500
Senior Notes 6.125 Percent Due 2028 [Member]
Debt Instrument [Line Items]
Face amount		$ 350,000
Debt Interest rate		6.125%
Proceeds from the issuance of senior unsecured notes, net of related discount		$ 343,900
Debt Instrument, Unamortized Discount		6,100
Debt Issuance Costs, Net		$ 2,300
Senior Notes 6.125 Percent Due 2028 [Member] | Redemption Period One
Debt Instrument [Line Items]
Debt Instrument, Redemption Price, Percentage		100.00%
Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed		40.00%
Debt Instrument Redemption Price Percentage, Proceeds From Equity Offerings		106.125%
Senior Notes 6.125 Percent Due 2028 [Member] | Redemption Period Two
Debt Instrument [Line Items]
Debt Instrument, Redemption Price, Percentage		103.063%
Senior Notes 6.125 Percent Due 2028 [Member] | Redemption Period Three
Debt Instrument [Line Items]
Debt Instrument, Redemption Price, Percentage		102.042%
Senior Notes 6.125 Percent Due 2028 [Member] | Redemption Period Four
Debt Instrument [Line Items]
Debt Instrument, Redemption Price, Percentage		101.021%
Senior Notes 6.125 Percent Due 2028 [Member] | Redemption Period Five and thereafter
Debt Instrument [Line Items]
Debt Instrument, Redemption Price, Percentage		100.00%

Stockholders' Equity (Details)

Stockholders' Equity (Details)	Aug. 04, 2020$ / sharesshares	Jul. 29, 2020$ / shares	Feb. 15, 2018USD ($)$ / shares	Sep. 30, 2020$ / sharesshares	Jul. 31, 2020USD ($)$ / sharesshares	Jun. 30, 2020$ / sharesshares	Sep. 30, 2020USD ($)$ / sharesshares	Mar. 31, 2019USD ($)	Sep. 30, 2020USD ($)$ / sharesshares	Sep. 30, 2019USD ($)	Dec. 31, 2019$ / shares	Nov. 08, 2019shares
Class of Stock [Line Items]
Shares issued									2,100,000
Offering costs | $								$ 837,000	$ 11,197,000	$ 837,000
Preferred stock, liquidation preference (in dollars per share) | $ / shares						$ 0.0001
Preferred stock, par value (in dollars per share) | $ / shares				$ 0.0001		$ 0.0001	$ 0.0001		$ 0.0001		$ 0.0001
Warrants and Rights Note Disclosure [Abstract]
Warrants outstanding				4,300,000			4,300,000		4,300,000
Common stock for each warrant exercised	0.3856
Warrant exercisable price | $ / shares	$ 11.50		$ 11.50
Warrants exercised in cashless transaction, number exercised									6,200,000
Warrants exercised for cash, number exercised									2,100,000
Public warrants, number redeemed									2,300,000
Proceeds from exercise of warrants | $									$ 24,495,000
Shares issued for warrants exercised									900,000
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 11.50		11.50
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right	0.3856
Warrant Cashless Exercise, Share Equivalent Of Exercise Price	0.6144
Warrant Cashless Exercise, Share Price Factor | $ / shares		$ 18.7175
Warrant Redemption Price | $ / shares	$ 0.01
Warrant Redemption, Stock Price Trigger | $ / shares			$ 18
Warrant Redemption, Threshold Consecutive Trading Days | $			30
Warrant Redemption, Threshold Trading Days | $			20
Earn-out consideration, shares per annual installment									1,000,000
First stock price hurdle (in dollars per share) | $ / shares									$ 15
Second stock price hurdle (in dollars per share) | $ / shares									18
Third stock price hurdle (in dollars per share) | $ / shares									$ 22
Earn-out consideration, total shares									3,000,000
Private Placement [Member]
Class of Stock [Line Items]
Proceeds from sale of stock | $					$ 190,000,000		$ 223,361,000
Offering costs | $					$ 1,600,000		1,639,000
Public Offering [Member]
Class of Stock [Line Items]
Proceeds from sale of stock | $							133,042,000
Offering costs | $							$ 9,558,000
Class A Common Stock
Class of Stock [Line Items]
Exchange of Series A Preferred Stock for Class A Common Stock (in shares)				2,900,000
Exchange of Class A Common Stock for Series B-1 Preferred Stock (in shares)						15,810,547
Shares of common stock received in conversion for each share of preferred stock						100
Preferred stock conversion, ceiling as a percent of outstanding common stock						4.9
Warrants and Rights Note Disclosure [Abstract]
Shares issued for warrants exercised									2,000,000
Class A Common Stock | Private Placement [Member]
Class of Stock [Line Items]
Shares issued					10,900,000
Class A Common Stock | Public Offering [Member]
Class of Stock [Line Items]
Proceeds from sale of stock | $					$ 142,600,000
Shares issued					9,200,000
Offering costs | $					$ 9,600,000
Share Price | $ / shares					$ 15.50
Series A Preferred Stock
Class of Stock [Line Items]
Exchange of Series A Preferred Stock for Class A Common Stock (in shares)				39,706
Series A Preferred Stock | Private Placement [Member]
Class of Stock [Line Items]
Shares issued					39,706
Series B Preferred Stock
Class of Stock [Line Items]
Exchange of Class A Common Stock for Series B-1 Preferred Stock (in shares)						158,105.47
Series B-1 Preferred Stock
Class of Stock [Line Items]
Exchange of Series B-2 Preferred Stock for Series B-1 Preferred Stock (in shares)				25,454.55
Series B-2 Preferred Stock
Class of Stock [Line Items]
Exchange of Series B-2 Preferred Stock for Series B-1 Preferred Stock (in shares)				35,000
Series B-2 Preferred Stock | Private Placement [Member]
Class of Stock [Line Items]
Proceeds from sale of stock | $					$ 35,000,000
Shares issued					35,000
Adapt Health Holdings LLC
Warrants and Rights Note Disclosure [Abstract]
Warrants outstanding												12,700,000
Common stock for each warrant exercised				1			1		1
Warrant exercisable price | $ / shares				$ 11.50			$ 11.50		$ 11.50
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares				$ 11.50			$ 11.50		$ 11.50
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right				1			1		1

Stockholders' Equity - Equity-b

Stockholders' Equity - Equity-based compensation (Details) - USD ($) shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Nov. 07, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Equity-based compensation expense	$ 5.5	$ 0.4	$ 11	$ 5.8
Accelerated vesting cost				$ 4.9
Unrecognized compensation expense	32.8		$ 32.8
Recognition period			2 years 10 months 24 days
General and administrative expenses
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Equity-based compensation expense	3.7		$ 7
Cost of Sales [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Equity-based compensation expense	$ 1.8		$ 4
2019 Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares authorized for issuance					8
Stock available for issuance	1.5		1.5

Stockholders' Equity - Common s

Stockholders' Equity - Common stock awards (Details) - USD ($) $ in Millions	1 Months Ended		3 Months Ended		9 Months Ended
	Aug. 31, 2020	May 31, 2020	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Equity-based compensation expense			$ 5.5	$ 0.4	$ 11	$ 5.8
Awards To Newly Hired Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted, shares	10,755	11,625
Equity-based compensation expense	$ 0.2	$ 0.2
Retention Program Awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted, shares		16,329
Equity-based compensation expense		$ 0.2

Stockholders' Equity - Options

Stockholders' Equity - Options activity and assumptions (Details) - Options - USD ($) $ / shares in Units, $ in Millions	1 Months Ended		9 Months Ended
	Apr. 30, 2020	Nov. 30, 2019	Sep. 30, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted	47,335	3,416,666
Options granted, exercise price	$ 16.25	$ 11.50
Grant date value	$ 0.3	$ 7.2
Expected volatility			40.70%
Risk-free interest rate			0.40%
Expected term			6 years

Stockholders' Equity - Restrict

Stockholders' Equity - Restricted stock (Details) - USD ($) $ / shares in Units, $ in Millions	1 Months Ended		3 Months Ended			9 Months Ended
	Apr. 30, 2020	Mar. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Equity-based compensation expense			$ 5.5		$ 0.4	$ 11	$ 5.8
Single Employee [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted, shares		300,000
Vesting percentage	33.00%	25.00%
Grant date fair value	$ 0.3	$ 4.9
Number of trading days	10 days
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Granted, shares		300,000
Various Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted, shares		323,510
Grant date fair value		$ 5.3
Equity-based compensation expense		0.3
Compensation cost, portion to be recognized over service period		$ 5
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Granted, shares		323,510
Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted, shares						2,050,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Non-vested balance at beginning of period						901,000
Granted, shares						2,050,000
Vested, shares						(44,000)
Forfeited, shares						(39,000)
Non-vested balance at end of period			2,868,000			2,868,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Non-vested, grant date fair value at beginning of period						$ 5.83
Granted, grant date fair value						18.32
Vested, grant date fair value						12.04
Forfeited, grant date fair value						10.85
Non-vested, grant date fair value at end of period			$ 14.54			$ 14.54
Restricted Stock | Single Employee [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted, shares	20,656
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Granted, shares	20,656
Restricted Stock | Various Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted, shares			450,369	77,896
Vesting period			3 years
Grant date fair value			$ 9	$ 1.2
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Granted, shares			450,369	77,896
Restricted Stock | Non-employee board members
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted, shares			37,198
Grant date fair value			$ 0.8
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Granted, shares			37,198
Vesting based on performance | Various Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted, shares			840,219
Grant date fair value			$ 16.1
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Granted, shares			840,219
Tranche 1 | Single Employee [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted, shares		250,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Granted, shares		250,000
Tranche 1 | Various Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted, shares		15,417
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Granted, shares		15,417
Tranche 2 | Single Employee [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted, shares		50,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Granted, shares		50,000
Tranche 2 | Various Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage		25.00%

Stockholders' Equity - Incentiv

Stockholders' Equity - Incentive Units (Details) - 2019 Incentive Plan - USD ($) $ in Millions	Nov. 08, 2019	Jun. 30, 2019
Equitybased Compensation
Vesting period	1 year
Grant date fair value		$ 4.5
Tranche 1
Equitybased Compensation
Vesting percentage		50.00%
Tranche 2
Equitybased Compensation
Vesting percentage		50.00%

Earnings Per Share (Details)

Earnings Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Earnings Per Share, Basic and Diluted [Abstract]
Net Income (Loss) Attributable to Parent	$ (2,489)	$ (3,686)	$ 1,386	$ (11,570)
Earnings allocated to participating securities			184
Net Income (Loss) Available to Common Stockholders, Basic	$ (2,489)	$ (3,686)	$ 1,202	$ (11,570)
Denominator:
Weighted Average Number of Shares Outstanding, Basic	57,372	21,721	47,986	19,130
Add: Warrants			1,438
Add: Contingent Consideration Shares			700
Add: Unvested restricted stock			724
Diluted weighted average common shares outstanding	57,372	21,721	50,848	19,130
Earnings Per Share, Basic	$ (0.04)	$ (0.17)	$ 0.03	$ (0.60)
Earnings Per Share, Diluted	$ (0.04)	$ (0.17)	$ 0.02	$ (0.60)

Leases - Capital leases (Detail

Leases - Capital leases (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Capital Leases, Future Minimum Payments Due, Rolling Maturity [Abstract]
2021	$ 19,845		$ 19,845
2022	1,241		1,241
Total	21,086		21,086
Less amount representing interest	(218)		(218)
Capital lease obligations	20,868		20,868
Current portion	(19,699)		(19,699)		$ (19,750)
Noncurrent	1,169		1,169
Equipment under capital leases
Equipment under capital leases
Cost of equipment under capital leases	38,600		38,600		39,100
Accumulated depreciation of equipment under capital leases	11,600		11,600		$ 11,700
Maximum
Capital Leased Assets [Line Items]
Interest expense related to capital leases	$ 100	$ 100	$ 100	$ 100

Leases - Operating (Details)

Leases - Operating (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Lease Commitments
Deferred rent	$ 1,300		$ 1,300		$ 1,100
Rent expense	4,600	$ 2,900	11,900	$ 7,600
Operating Leases, Future Minimum Payments Due, Rolling Maturity [Abstract]
2021	17,914		17,914
2022	13,945		13,945
2023	11,515		11,515
2024	9,187		9,187
2025	6,181		6,181
Thereafter	16,854		16,854
Lease commitments	75,596		75,596
Minimum annual lease commitments under noncancelable leases
Minimum sublease rentals	$ 2,100		$ 2,100

Income Taxes (Details)

Income Taxes (Details) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Income Taxes
Income Tax Expense (Benefit)	$ (636,000)	$ 1,027,000	$ 2,290,000	$ 5,444,000
Uncertain tax positions	$ 0		$ 0		$ 0
Tax Receivable Agreement, payout percentage			85.00%
Increase in liability due to additional exchanges			$ 26,700,000
Increase in deferred tax asset			23,000,000
Liability related to TRA			$ 38,100,000		$ 10,800,000

Commitments and Contingencies (

Commitments and Contingencies (Details)	1 Months Ended	9 Months Ended
	May 31, 2018USD ($)	Sep. 30, 2020USD ($)
Commitments and Contingencies.
Accrual related to lawsuits, claims, investigations and proceedings		$ 0
Number of subsidiaries	1
Agreement Term		5 years

Related Party Transactions (Det

Related Party Transactions (Details) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2020USD ($)	Sep. 30, 2019USD ($)	Sep. 30, 2020USD ($)item	Sep. 30, 2019USD ($)
Investor
Related Party Transaction [Line Items]
Loan from related party	$ 143.5		$ 143.5
Vendor two
Related Party Transaction [Line Items]
Number of executives | item			2
Ownership interest, as a percent	1.00%		1.00%
Expense for related party	$ 0.6	$ 0.6	$ 1.7	$ 1.5

Subsequent Events - Financing a

Subsequent Events - Financing and Acquisitions (Details) - Subsequent Event - Pinnacle Medical Solutions, Inc. [Member] shares in Millions, $ in Millions	Oct. 01, 2020USD ($)shares
Subsequent Event
Interest acquired, as a percent	100.00%
Cash payment	$ 81.5
Issuance of common stock for acquisitions (in shares) | shares	1
Stock available for issuance | shares	0.2
Contingent consideration	$ 15
Escrow payment	$ 2.6